University of Wollongong

Research Online
University of Wollongong Thesis Collection
2017+

University of Wollongong Thesis Collections

2020

To investigate the rates and contributing factors to adverse drug events for
patients treated with non-vitamin K antagonist oral anticoagulants versus
warfarin, a vitamin K antagonist
Kerry Louise Watts

Follow
thisofand
additional works at: https://ro.uow.edu.au/theses1
University
Wollongong
University of Wollongong
Copyright Warning
You may print or download ONE copy of this document for the purpose of your own research or study. The University
does not authorise you to copy, communicate or otherwise make available electronically to any other person any
copyright material contained on this site.
You are reminded of the following: This work is copyright. Apart from any use permitted under the Copyright Act
1968, no part of this work may be reproduced by any process, nor may any other exclusive right be exercised,
without the permission of the author. Copyright owners are entitled to take legal action against persons who infringe
their copyright. A reproduction of material that is protected by copyright may be a copyright infringement. A court
may impose penalties and award damages in relation to offences and infringements relating to copyright material.
Higher penalties may apply, and higher damages may be awarded, for offences and infringements involving the
conversion of material into digital or electronic form.
Unless otherwise indicated, the views expressed in this thesis are those of the author and do not necessarily
represent the views of the University of Wollongong.

Recommended Citation
Watts, Kerry Louise, To investigate the rates and contributing factors to adverse drug events for patients
treated with non-vitamin K antagonist oral anticoagulants versus warfarin, a vitamin K antagonist, Master
of Philosophy thesis, School of Medicine, University of Wollongong, 2020. https://ro.uow.edu.au/theses1/
951

Research Online is the open access institutional repository for the University of Wollongong. For further information
contact the UOW Library: research-pubs@uow.edu.au

Thesis | Kerry Watts

To investigate the rates and contributing factors to adverse drug events for patients treated with
non-vitamin K antagonist oral anticoagulants versus warfarin, a vitamin K antagonist

A thesis submitted in fulfilment of the requirements for the award of the degree

Master of Philosophy

from
University of Wollongong
by

Kerry Louise Watts, Bachelor of Pharmacy

Faculty of Science, Medicine and Health

2020

Page | 0

Thesis | Kerry Watts

CERTIFICATION

I, Kerry Louise Watts, declare that this thesis is wholly my own work unless otherwise
referenced or acknowledged. The document had not been submitted for qualifications at any
other academic institution.

Kerry Louise Watts
March, 2020

Page | 1

Thesis | Kerry Watts

ACKNOWLEDGEMENTS

This research has been conducted with support of the Australian Government Research Training
Program Scholarship.

I would like to acknowledge the Illawarra Health Information Platform (IHIP) research
partnership established between the Illawarra Shoalhaven Local Health District (ISLHD) and the
University of Wollongong for providing the hospitalised data used in this study. I would also
like to acknowledge Department of Human Services Australia for the supply of PBS data to
provide population data used in this study.

I would like to give thanks to my supervisors without whom this thesis would never have been
possible. Firstly, my primary supervisor Associate Professor Judy Mullan for accepting to
support me through this journey, sharing with me her wealth of knowledge and providing me
with direction, guidance, moral support and continued patience to enable me to achieve my
goals. Secondly, Dr Luise Lago for her advice on study design and statistical genius to guide me
through the complexities of a logistic regression model. I would like to thank Margaret Jordan
for her inspiration to start on this journey, her professional guidance and astute attention to detail
and lastly Associate Professor Laurencia Villalba for sharing a passion for patient centred care
and promoting safe use of medicines.

I would like to give the greatest thanks for my husband, not only for his emotional support and
keeping the house clean while I have been completing this research, but also for providing the
professional support I needed to complete medical record reviews when the task appeared
impossible. Without him, this research would never have been possible.

Page | 2

Thesis | Kerry Watts

ABSTRACT

Introduction

An adverse drug event (ADE) for this thesis is defined as harm from a medication resulting in
hospitalisation. Oral anticoagulants are among the most common drugs worldwide which
contribute to medication-related ADEs. These oral anticoagulants include the non-vitamin K
antagonist oral anticoagulant (NOACs) and warfarin, a vitamin K antagonist. According to the
evidence, there are conflicting studies which have cited significant and non-significant
differences between NOACs and warfarin, with regard to ADEs, including haemorrhage,
ischaemic stroke and venous thromboembolism (VTE). The majority of these studies have been
clinical trials and do not include post-marketing surveillance. This thesis compares populationadjusted rates and risk of ADEs for NOACs (apixaban and rivaroxaban) and warfarin for a
cohort of patients residing in the Illawarra Shoalhaven region of NSW. In addition, this study
investigated potential contributing factors for oral anticoagulant-related ADEs resulting in
hospitalisation.

Methods

There are two studies within this thesis. The first study was a retrospective observational cohort
study of residents within the Illawarra Shoalhaven Local Health District prescribed oral
anticoagulants between July 1st 2015 and June 30th 2017. This study utilised Pharmaceutical
Benefits Scheme (PBS) aggregate data and unit record hospitalisation data using ICD-10 AM
(9th edition) and SNOMED codes for haemorrhage, VTE and ischaemic stroke, for persons
taking NOACs (apixaban or rivaroxaban) or warfarin. Statistical analysis included modelling
relative risk and logistic regression to calculate adjusted odds ratios for ADEs requiring
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hospitalisation among individuals taking NOACs compared to warfarin, accounting for sex, age
and geographic region. Further contributing factors investigated included renal function,
comorbidities and thrombophilia. The second study was a small prospective pilot study which
explored knowledge about anticoagulants, using the Medication Knowledge Tool, and
medication adherence, using the Morisky Medication Adherence Questionnaire, among vascular
outpatients with recurrent VTE who were taking NOACs (apixaban or rivaroxaban).

Results

In 585 of 9,432 hospitalisations for an ADE (haemorrhage, VTE or ischaemic stroke), the
individual was taking an oral anticoagulant. An analysis of these 585 hospitalisations found,
when compared to those taking warfarin, individuals taking a NOAC had less risk of
hospitalisation for an ADE (aOR 0.71, 95% CI 0.60-0.85), including approximately half the risk
of being hospitalised for an ischaemic stroke ADE (aOR 0.51, 95% CI 0.34-0.78). Specifically,
when compared to warfarin, individuals taking apixaban had less risk of a total haemorrhagic
ADE (aOR 0.46, 95% CI 0.34-0.62), lower rates of hospitalisation for clinically relevant nonmajor bleeding events (7.7 per 1,000 prescribed per year vs 14.0 per 1,000 prescribed per year),
and lower risk of a major haemorrhagic event (2.3 per 1,000 prescribed per year vs 6.0 per 1,000
prescribed per year). In contrast, compared to warfarin, individuals taking rivaroxaban were
more than twice as likely to be hospitalised for a VTE ADE (aOR 2.02, 95% CI 1.04-3.92), and
compared to apixaban, individuals taking rivaroxaban were more than twice as likely to be
hospitalised for a VTE ADE (aOR 2.78, 95% CI 1.16-6.76). The findings of the retrospective
observational cohort study also suggest that thrombophilia and renal impairment are potential
contributing factors for oral anticoagulant-related ADEs resulting in hospitalisation and requires
further investigation on a much larger scale.
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The small-scale prospective pilot study recruited nine participants. Knowledge of apixaban or
rivaroxaban was 58.5%, and only two participants knew the most important side effects of their
anticoagulants, while only one participant knew that skipping a dose of a NOAC could worsen
their condition. Medication adherence was found to be medium to high among the nine
participants. Due to the small number of participants in this study, it was not possible to
investigate if knowledge and adherence were contributing factors to recurrent VTE.

Discussion

This research suggests the importance to patients, prescribers and the health system, of
understanding the risks associated with taking oral anticoagulants based on a cohort which
reflects the realities of comorbid conditions and medication knowledge. This research suggests
there was a lower overall risk of hospitalisation for ADEs, including major haemorrhage and
ischaemic stroke, for individuals taking NOACs compared to warfarin. In contrast, individuals
taking warfarin had a much lower risk of experiencing VTE ADEs, which potentially suggests
that it is a safer option for the treatment and/or prevention of VTE compared to rivaroxaban.
Further national population studies are needed to compare the risk of ADEs between NOACs
and warfarin to confirm and expand on these findings due to limitations in the available data.
There would then be potential to review current practice guidelines recommending all NOACs
as first line for VTE treatment and/or prophylaxis.
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List of abbreviations and acronyms
ADE

adverse drug event

AF

atrial fibrillation

aOR

adjusted odds ratio

CHRISP

Centre for Health Research Illawarra Shoalhaven Population

CrCl

creatinine clearance

CRNMB

clinically relevant non-major bleed

DAEN

Database of Adverse Event Notifications

DVT

deep vein thrombosis

ED

emergency department

eMR

electronic medical records

GI

gastrointestinal

GP

general practitioner

Hb

haemoglobin

ICD-10-AM

The International Statistical Classification of Diseases and Related Health
Problems, Tenth Revision, Australian Modification

IHIP

Illawarra Health Information Platform

ISLHD

Illawarra Shoalhaven Local Health District

INR

International Normalised Ratio

NOAC

non-vitamin k antagonist oral anticoagulant
Page | 6

Thesis | Kerry Watts

NVAF

non-valvular atrial fibrillation

OR

odds ratio

PBS

Pharmaceutical Benefits Scheme

PE

pulmonary embolism

RR

relative risk

SA

Statistical Area

SNOMED-CT Systematized Nomenclature of Medicine- Clinical Terms
VKA

vitamin K antagonist

VTE

venous thromboembolism
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1. INTRODUCTION

1.1 Introduction

From the time of their introduction, NOACs have been marketed as a superior and more
convenient treatment option compared to warfarin, because of their fixed dosing regimens and
no requirement for routine coagulation monitoring (Connell & Butera 2015). Figure 1
illustrates the rapid uptake of NOACs in clinical practice for Non-valvular Atrial Fibrillation
(NVAF) and decline in warfarin use, since the listing of the NOACs on the PBS in Australia.
NOACs have promptly been accepted as the preferred treatment choice by many healthcare
practitioners (Connell & Butera 2015). Although warfarin remains the most prescribed oral
anticoagulant, since 2015, Australian patients starting oral anticoagulant therapy for the first
time have been more likely to be commenced on a NOAC, rather than on warfarin (Department
of Health. 2016). Furthermore, Australian guidelines now recommend NOACs over warfarin for
NVAF (Brieger et al. 2018) and clinicians treating VTE are advised to prescribe a factor Xa
inhibitor as the first choice anticoagulant (Tran et al. 2019).
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*DUSC and DHS supplied prescriptions (accessed March 2016). Includes private, under co‐payment and actual
(PBS).

Figure 1- Number of anticoagulant prescriptions supplied from 2010 to 2015

In addition to being useful treatment and prophylactic medications, oral anticoagulants also
contribute to the ADE profile in Australia. An adverse event is classified as any harmful event
which occurs during treatment with a drug, without the necessity to link the event with the action
of the drug (Simper et al. 2017). An adverse drug event (ADE) is an injury resulting from the use
of a drug and encompasses adverse drug reactions (ADRs) which include an unintended
response to a drug at normal dose range, medication errors and overdoses (Piazza et al. 2011).
An ADE for the purpose of this thesis is defined as an event that caused severe harm to an
individual from medication use that resulted in an unplanned hospitalisation.

ADEs range is severity from mild, self-resolving events, which may not necessitate an
intervention and can be managed without hospitalisation (Marsh 2018) to severe events which
require initial or prolonged hospitalised medical interventions (Food and Drug Administration.
2016). Oral anticoagulants are among the most common medication which have contributed to
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ADEs that required hospitalisation in NSW, Australia (13.5%; n=315,274) (Zhang et al. 2019).
Haemorrhages, of varying types, are the most commonly reported ADEs while taking oral
anticoagulation (Anderson & Cifu 2018).

Hospitalisation for anticoagulant related events may also be due to treatment failure, which
includes the occurrence of primary or recurrent venous thromboembolism (VTE) or ischaemic
stroke (McIlroy et al. 2018). VTE is the blockage of a blood vessel by a clot and accounts for
14,000 hospitalisations in Australia each year (Clinical Excellence Commission 2014). This
condition includes both deep vein thrombosis (DVT), a clot in the deep venous system, most
commonly in the legs; and pulmonary embolism (PE), a blood clot that breaks away from the
deep veins and blocks the pulmonary arteries of the lungs (AMH 2018; Clinical Excellence
Commission 2014). Oral anticoagulants are the most common medications used for the
treatment and prevention of VTE and are also indicated for non-valvular atrial fibrillation
(NVAF), the most common cause of ischaemic stroke. An estimated 250,000 Australians are
currently taking, or have been prescribed, oral anticoagulants (Scott 2017). For almost 60 years,
warfarin, a vitamin K antagonist (VKA), had been the only oral anticoagulant available in
Australia (Kakkos et al. 2014). More recently, non-vitamin K antagonist oral anticoagulants
(NOACs), also referred to as direct oral anticoagulants (DOACs) (McCaughan 2017), became
accessible, providing clinicians a choice of therapy. There are currently three NOACs available
in Australia, defined by their mechanism of action; apixaban and rivaroxaban are factor Xa
antagonists and dabigatran, a direct thrombin inhibitor (AMH 2018; Chin & Doogue 2016).

The Pharmaceutical Benefits Scheme (PBS) provides subsidised prescription drugs to Australian
residents (Department of Health 2019) and is a good source of population rate analysis for
medication usage. The PBS was first introduced in the mid to late 1940s with a focus on
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expensive and life-saving drugs, not becoming fully comprehensive until 1960 (Goddard 2014).
When warfarin became approved for human use in Australia in 1954 (Kamien 2006), the PBS
was new and subsidy item codes issued for warfarin were based on the drug strength rather than
subset codes for each indication for use. The unavailability of PBS subset codes for warfarin
eliminates the scope to make direct retrospective comparisons of ADEs between oral
anticoagulants by indication. In 2013, rivaroxaban, and later in 2015, apixaban, gained PBS
approval for stroke prevention in NVAF and the treatment and prevention of VTE (Chin &
Doogue 2016; Department of Health 2016; Pratt et al 2016). Although dabigatran gained PBS
subsidisation for use in stroke prevention in 2013, it did not gain subsidisation for use in the
prevention of recurrent VTE. Therefore, dabigatran cannot be used to investigate direct
comparisons for rates of ADEs for all indications with rivaroxaban, apixaban and warfarin,
which is why dabigatran has been omitted from this research.

During the financial years July 2015 to June 2019, the Australian Therapeutics Goods
Association (TGA) Database of Adverse Event Notifications (DAEN), which is dependent on
voluntary reporting, found that oral anticoagulant therapies (apixaban, rivaroxaban and warfarin)
contributed to 980 of the reported ADEs in Australia, which primarily included VTEs,
haemorrhage and stroke (Department of Health 2019). However, the DAEN identified
considerably more ADEs associated with both rivaroxaban (n= 524) and apixaban (n= 342) use,
between 2015 and 2019, compared to warfarin (n=114) (Department of Health 2019). Existing
literature has found, when compared to warfarin, apixaban poses lower risk of stroke and major
bleeding, while rivaroxaban poses similar risks of stroke and major bleeding (Yao et al. 2016).
Early studies have shown no significant difference in VTE recurrence rates between NOACs and
warfarin (Castellucci et al. 2014; Streiff et al. 2016).
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A Pharmaceutical Society of Australia conference presentation by the Master’s candidate, was
based on the findings of a pilot study which reviewed retrospective admissions to an Australian
principal referral hospital between January and June 2016 (Watts 2017). The pilot study found
that 37 of 260 (14.2%) admissions for VTE (ICD-10-AM (9th edition) codes I80.0, I80.2, I82.8,
I260 and I269) were among individuals taking oral anticoagulants on admission (14 taking
rivaroxaban, 19 taking warfarin and 4 taking apixaban), suggesting comparison of ADEs
between oral anticoagulants merited further investigation.

Based on the evidence that at least 50% of all ADEs are preventable (Simper et al. 2017; Woo et
al. 2020) and the majority of oral anticoagulant ADEs (53% NOAC and 61% warfarin) are also
preventable (Sennesael et al. 2018), this thesis explores several physiological and preventable
behavioural factors that are believed to contribute to oral anticoagulant-related ADEs, some of
which are difficult to ascertain based on limited evidence. For example, the eligibility criteria for
randomised controlled trials are often very strict and exclude people living with comorbid
conditions, such as renal impairment and thrombophilia, which may negatively impact upon
patient outcomes (Burness & Perry 2014; NPS 2013). Existing literature is sparse regarding the
impact of poor patient knowledge and medication adherence to NOACs, as compared to warfarin
and their impact of ADEs. Furthermore, there is a paucity of population-based research into the
ADEs and treatment failure of NOACs when taken for any indication in the post-marketing
period, which is why there is an urgent need for a comparative investigation of warfarin and
NOACs, which may provide invaluable future guidance for prescribing physicians.

Based on the limited post-marketing research of ADEs for NOACs versus warfarin and the
preliminary findings from the pilot study (undertaken by the Master’s candidate), this thesis
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describes the research which investigated and compared the rates of NOAC and warfarin-related
ADEs for any indication, which resulted in hospitalisation.

1.2 Thesis aims and hypotheses

The principal aim of this research was to compare the rates of adverse drug events for
individuals prescribed oral anticoagulants warfarin (vitamin K antagonist) and the non-vitamin
K antagonists, apixaban and rivaroxaban, for all indications.

There were two secondary aims for this research:
1. To identify contributing factors to ADEs with the oral anticoagulant warfarin (vitamin K
antagonist) and the non-vitamin K antagonists, apixaban and rivaroxaban, for all
indications.
2. To explore whether patient knowledge or adherence were potential contributing factors
to recurrent VTE while treated with apixaban or rivaroxaban for DVT or PE.

There were three hypotheses for this research:
1. Rates of VTE ADEs were higher among patients taking NOACs than patients taking
warfarin.
2. Rates of haemorrhage and ischaemic stroke ADEs were no different among patients
taking NOACs compared to warfarin.
3. Impaired renal function, comorbidities, age, sex, residential region, poor patient
knowledge and medication adherence were contributing factors to ADEs among patients
taking oral anticoagulants.
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2. LITERATURE REVIEW

2.1 Introduction

Oral anticoagulants are the primary medication therapy used to treat and help prevent VTE,
essentially DVT and PE (Bauer 2013), with an incidence rate in Australia of 1.5 per 1,000
people per year (Stevens et al. 2019). Oral anticoagulants are also indicated in stroke prevention
for ‘at risk’ patients living with NVAF (Basaran et al. 2015), however atrial fibrillation (AF) is
the not the main focus of this research and has been included to facilitate a robust comparison
between warfarin and NOACs using PBS prescription data.

This literature review will compare and contrast warfarin and NOACs (apixaban and
rivaroxaban) in terms of their pharmacokinetic profiles, potential for ADEs, and factors that can
affect their therapeutic responses.

2.2 Search strategies

The MEDLINE database on the OVID® platform was searched between 2010 and 2020, using
the search terms: venous thromboembolism, VTE, pulmonary embolism, PE, recurrence,
haemorrhage, ischaemic stroke, Eliquis®, apixaban, rivaroxaban, Xarelto®, warfarin,
Coumadin®, Marevan® and adverse drug event. The search strategy can be found in Appendix
1.

The search yielded 6,278 articles. Application of the inclusion criteria depicted in Figure 2,
which included articles published post 2010, written in English and review articles with human
participants resulted in the exclusion of 6,150 articles. In addition to the 128 articles identified
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from the search strategy and inclusion criteria, articles pertaining to prescribing habits, which are
not indexed in international literature, were also included in the literature review. These articles
were sourced by searching Google Scholar® and the grey literature and resulted in an additional
17 articles/references. In total, 145 articles/references were screened for relevance and a further
83 were excluded because they were based on other ADEs not relevant to anticoagulants,
alternate therapies or specific population groups, for example cancer, that are not the focus of
this thesis.

Figure 2- PRISMA Flow Diagram
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2.3 Literature review findings

In total, 62 articles contributed to this review. These included seven medication information data
bases, for example the Australian Medicines Handbook, and Australian government guidelines.
The articles included four systematic reviews and meta-analyses, eight quantitative studies,
seven randomised clinical trials, thirty-two literature reviews and four case reports. The majority
of the articles (n=51) were conducted in the United States (US), Canada, the United Kingdom
(UK) and Europe, with only four studies conducted in Australia.

The following provides a summary of key findings from the literature review under five
subheadings: ADEs; Mechanism of action and pharmacokinetics of oral anticoagulants; Current
prescribing patterns of oral anticoagulants in Australia; Potential ADEs associated with oral
anticoagulants; and Contributing factors to ADEs.

2.3.1 Adverse drug events

Adverse Drug Events (ADEs) include injuries resulting from the use of a drug, and includes
harm caused by Adverse Drug Reactions (ADRs), harm from the use of the drug (including dose
reductions and discontinuations), as well as harm from medication errors (Piazza et al. 2011).
ADRs range from common side-effects, including gastrointestinal upset; to allergic reactions,
including rash; or even life threatening anaphylaxis (Smith 2013). Most ADRs are dose-related
and predictable (Marsh 2018). Conversely, medication errors are defined by unpredictable
inaccuracies in prescription, transcription, dispensing or administration of medications
(Runciman et al. 2003). A US study, which investigated 463 anticoagulant-associated
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hospitalisations for ADEs, found that 226 hospitalisations were the result of medication errors
(48.8%) and 141 were ADRs (30.5%) (Piazza et al. 2011).

In total, ADEs in the US, account for an estimated 1 million ED visits and 125,000 hospital
admissions per year (U.S. Department of Health and Health Services 2020), while in Australia it
is estimated that 2 to 3% of all hospital admissions per year are medication related (Australian
Commission on Safety and Quality in Healthcare 2017). Due to these estimates, developing
strategies to reduce ADEs have been made a national health priority (Australian Commission on
Safety and Quality in Healthcare 2017), primarily because a large proportion of these ADEs are
deemed to be preventable (Snyder & Fields 2010). According to the literature, between 28 and
80% of all ADEs are preventable (Woo et al. 2020) and up to 70% of all anticoagulantassociated ADEs are preventable (Piazza et al. 2011; Runciman et al. 2003). Given that this high
proportion of anticoagulant related ADEs are potentially preventable, there is clearly a need for
further research to compare the number of severe ADEs associated with the different
anticoagulants and factors which may contribute to the ADEs.

2.3.2 Mechanism of action and pharmacokinetics of oral anticoagulants

Currently available oral anticoagulants prescribed for the treatment and/or prevention of VTE
include warfarin, apixaban and rivaroxaban. Warfarin is a vitamin K antagonist (Table 1), that
inhibits the vitamin K-dependent synthesis of clotting factors II,VII, IX and X in the liver
(Vandiver et al. 2014), and decreases the natural anticoagulant regulatory proteins C and S
(Minuk et al. 2010); thus reducing the coagulant ability of the blood and helping to treat and
prevent VTE. Apixaban and rivaroxaban selectively inhibit clotting factor Xa (Table 1),
blocking thrombin production and the conversion of fibrinogen to fibrin (Bauer 2013).
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Warfarin is completely absorbed after oral administration (Tadros & Shakib 2010) and hepatic
enzymes, cytochrome P450 (CYP) (Table 1) are responsible for the metabolism and elimination
of warfarin (Tadros & Shakib 2010). Although warfarin demonstrates a peak concentration time
of four hours (Table 1), the peak therapeutic effect may not be achieved until 72 to 96 hours
after administration (Medscape 2016). The long half-life of warfarin (20-60 hours) is directly
related to the long half-lives of the vitamin K-dependant clotting factors, as well as the C and S
proteins (Kaztung et al. 2017). Due to the delayed onset of therapeutic action of warfarin, when
used for the treatment of VTE, a bridging period with an injectable anticoagulant is required
until a therapeutic level is established (Hillis & Crowther 2014).

Individualised dosing is required with warfarin therapy because of its narrow therapeutic index
and unpredictable pharmacokinetics (Hillis & Crowther 2014; Viprey et al. 2017). The
therapeutic level of warfarin is expressed numerically as a surrogate measure of the time taken
for the blood to clot, commonly known as the international normalised ratio (INR) (Nelson et al.
2015). The aim of therapy is to keep the INR between 2 and 3 and the ‘time the INR spends in
therapeutic range’ (TTR) should be above 70% to avoid treatment failure (Jordan 2015). This is
important because an INR below 2 is subtherapeutic and increases the risk of thromboembolism,
whereas an INR above 3 is supratherapeutic and increases the risk of haemorrhage events,
especially among older people (Ahmad & Lip 2012).

In contrast to warfarin, apixaban and rivaroxaban display predictable pharmacokinetics, with a
rapid onset of action, resulting in a therapeutic response within one hour (McBane & Marshall
2017) and a peak concentration within three hours (Table 1). This rapid onset of action means
that unlike warfarin, there is no requirement for bridging with an injectable anticoagulant for the
treatment of VTE (Hillis & Crowther 2014; Viprey et al. 2017). Furthermore, NOACs
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demonstrate a much shorter half-life (5-14 hours) than warfarin (Table 1) signifying that regular
dosing is imperative for maintaining therapeutic levels as the anticoagulant effect dissipates
quickly.

Although both NOACs and warfarin undergo metabolism by hepatic CYP enzymes, warfarin is
almost completely metabolised in the liver (99%), as compared to the NOACs which are mainly
eliminated via the renal system (Table 1). In contrast to warfarin, 25% of apixaban and 33% of
rivaroxaban are excreted by the renal system (Hinojar et al. 2015) and the remainder converted
in the liver or eliminated in the faeces (Bauer 2013). Therefore, kidney function and potentially
liver function are important considerations when NOACs are prescribed.

Table 1- Mechanism of action and pharmacokinetics of anticoagulants (AMH 2018; MIMS
Australia 2016; Vandiver et al. 2014)
Anticoagulant
Mechanism of action

Warfarin
Vitamin K

Apixaban
Direct factor Xa

Rivaroxaban
Direct factor Xa

antagonist

inhibitor

inhibitor

Half life

20-60 hours

9-14 hours

5-13 hours

Time to peak

4 hours

3 hours

3 hours

Renal excretion

Nil

25%

33%

Renal Contraindications

Nil

CrCl <25mL/min

CrCl <30mL/min

CYP enzyme metabolism

99%

15%

32%

Key: CrCl= Creatinine Clearance. This is a surrogate measure of kidney function by estimating the rate that
creatinine is cleared.

2.3.3 Current prescribing patterns of oral anticoagulants in Australia

In 2015, there were approximately 250,000 Australians receiving prescriptions for oral
anticoagulants (Scott 2017). Prior to and since that time, the number of Australians being
prescribed NOACs has been steadily increasing. For example, prescriptions for rivaroxaban for
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VTE prophylaxis after orthopaedic surgery, have increased from 100,000 in 2013 to almost 1.5
million in 2016, while prescriptions for warfarin have declined from 2.45 million in 2012 to 1.85
million in 2016 (Department of Health 2016). In 2015, patients starting oral anticoagulant
therapy for NVAF, for the first time, were more likely to commence on a NOAC rather than
warfarin (Department of Health 2016). The NOAC prescription numbers continued to increase
as apixaban or rivaroxaban became the preferred anticoagulation among Australian prescribers
for treatment and prophylaxis of VTE (Stevens et al. 2019), particularly for individuals with
unstable INR likely to miss follow up appointments (Generalova et al. 2018). Clinician
knowledge of the dosing complexities of NOACs for the treatment and prevention of VTE could
be a major contributing factor to the risk of ADEs. For example, NOACs have been promoted as
having simplistic dosing regimens which do not require regular monitoring (Vutukuri et al.
2015). In comparison to the daily dosing schedule for warfarin, Table 2 outlines the multiple
dosing schedules required for NOACs depending on the different indications. It is recommended
that high risk individuals with complicated comorbidities, or previous recurrent VTE while
taking rivaroxaban 10 mg daily, are to be prescribed a higher dose of rivaroxaban (20 mg daily)
(Electronic Medicines Compendium 2018). The complicated dosing regimen for NOACs is a
potential contributing factor for ADEs, especially when the Australian guidelines for NVAF
were updated in 2018 to recommend NOACs as first choice over warfarin (Brieger et al. 2018)
and clinicians treating acute VTE were advised to prescribe factor Xa inhibitors as the first
choice anticoagulant (Tran et al. 2019).

Page | 26

Thesis | Kerry Watts

Table 2- Complex fixed-dose regimens for treatment and prevention of VTE
NOAC

Apixaban

Rivaroxaban

Prevention of VTE in hip/knee
replacement

2.5 mg twice daily

10 mg once daily

Duration: hip 32-38 days; knee

Duration: hip 5 weeks; knee 2

10-14 days

weeks

10 mg twice daily for 7 days

15 mg twice daily for 3 weeks

then 5mg twice daily

then 20 mg once daily

2.5 mg twice daily after at least

10mg or 20 mg once daily for

6 months of treatment of DVT

up to 12 months

Treatment of VTE
Prevention of recurrent VTE

or PE
* Retrieved from MIMS Australia (2016).

2.3.4 Potential adverse events associated with oral anticoagulants

All oral anticoagulants have the potential to cause ADEs resulting in unplanned hospitalisations,
which include haemorrhage (bleeding) (Khan & Datta 2015) or treatment failure, including VTE
events (Lutsey et al. 2019) and ischaemic stroke while taking an oral anticoagulant (Brieger et
al. 2018).

2.3.4.1 Haemorrhage

Bleeding is the most common ADE reported with oral anticoagulant use and can be life
threatening, so the benefits and risks of anticoagulation require careful consideration before
commencing therapy (Khan & Datta 2015). The evidence regarding the incidence of all bleeding
events associated with taking either warfarin or NOACs is variable and inconsistent. A review of
Phase III clinical trials report higher bleeding events within 6 to 12 months of warfarin therapy
(10%), in comparison to NOACs (4%–9%) (Toth 2016). However, a longitudinal Danish study
which included 61,678 patients prescribed oral anticoagulation for AF, between 2011 and 2015,

Page | 27

Thesis | Kerry Watts

found comparable total annual bleeding events for warfarin (5.0%; n=35,436) and rivaroxaban
(5.3%; n= 7,192) but lower for apixaban (3.3%; n= 6,349) (Larsen et al. 2016). The evidence is
conflicting regarding the bleeding-related ADEs associated with both NOACs and warfarin,
therefore requiring further investigation in a real-world post phase III clinical trial setting.
Another area worth investigating in a real-world setting, is the difference in the severity of
adverse bleeding events for both warfarin and NOACs which can range in severity from nonmajor to major bleeding events (Khan & Datta 2015).

Clinically relevant non-major bleeding events

Clinically relevant non-major bleeds (CRNMB) are haemorrhagic events which require
healthcare intervention and include, but are not limited to, epistaxis (nose bleeds) and mild rectal
bleeds (Khan & Datta 2015). Studies have cited the benefits of NOACs in comparison to
warfarin, especially with regard to the reduction in CRNMB (Adam et al. 2013; Rollins et al.
2014; Van Es et al. 2014). These findings concur with an Australian study, that reported on 379
hospital admissions with a primary diagnosis of minor bleeding (Roberts et al. 2016). In this
study, hospital admissions were more prevalent for patients taking warfarin, as compared to
patients taking NOACs (17.8/1,000 years versus 5.2/1,000 years, respectively) (Roberts et al.
2016). However, in contrast to these findings, a review of 8,000 participants with a mean age of
between 55 and 58 years, included in the EINSTEIN DTV and EINSTEIN PE trials, reported no
significant difference in CRNMB events between rivaroxaban (28.3%) and warfarin (28.0%)
(Burness & Perry 2014). The exception to these results were the elderly patient population, aged
75 years and above, who experienced higher rates of CRNMB bleeding with rivaroxaban when
compared to warfarin (Burness & Perry 2014). This conflicting evidence suggests that more
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research is required to ascertain whether NOACs or warfarin are more or less likely to contribute
to CRNMB.

Major and gastrointestinal bleeding events

The definition for major bleeding encompasses more than a 2 gram/Litre drop in haemoglobin,
bleeding into a critical site, including intracranial bleeding, and the requirement for blood
transfusions (Beyer-Westendorf et al. 2014). Gastrointestinal (GI) haemorrhage is often
classified as a major bleed and is well documented while taking oral anticoagulants. In their
analysis of 13,130 patients, Abraham et al (2017) found that apixaban was the preferred NOAC
in patients at risk of GI bleeding, demonstrating a significant reduction (P<0.001) in the
incidence of GI haemorrhage when compared to rivaroxaban (1.34/100 patient years versus
3.54/100 patient years). These findings are supported by a US study, which investigated 32,350
patients, and reported significantly higher (P=0.03) GI bleeding in patients taking rivaroxaban
(3.26/100 person years), as compared to those taking warfarin (2.53/100 person years) (Amin et
al. 2017). Notably, another study, which included 18,201 patients, found that there was no
significant difference in GI haemorrhagic events between apixaban (0.76% events per year) and
warfarin (0.86% events per year) (Granger et al. 2011).

In contrast to this evidence, a systematic review and meta-analysis which included nearly 38,000
participants from Phase III clinical trials, found that lower rates of major bleeding events have
been associated with NOACs (1.08%) compared to warfarin (1.73%) (Kakkos et al. 2014). In
support of these findings, another Phase III trial provided evidence for the reduction of
intracranial haemorrhage events with NOACs when compared to warfarin (Van Es et al. 2014).
Similarly, Granger et al (2011) found that less than half the reported major bleeding events were
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experienced among patients treated with apixaban (0.33% per year), as compared to those
treated with warfarin (0.80% per year).

Overall, lower rates of major haemorrhagic events were documented for rivaroxaban when
compared to warfarin, however these are not as common as the marked increase in
gastrointestinal bleeding events (Amin et al. 2017). Apixaban, a relatively new NOAC, appears
to be associated with fewer bleeding related ADEs compared to the other oral anticoagulants,
including both rivaroxaban and warfarin. These findings, are based on clinical trials which are
often funded by drug companies and exclude participants with co-morbid risk factors, such as
hypertension, renal impairment and high risk of bleeding, which may have an impact on the
results (Kakkos et al. 2014). In addition, individuals may only require NOAC treatment for six
months (AMH 2018), however considerable haemorrhagic events have been found within 30
days of rivaroxaban initiation (Chen et al. 2016). This highlights the importance of considering
bleeding risk on initiation of treatment and the need for further comparative studies to
investigate whether NOACs are less likely than warfarin to cause bleeding related ADEs in a
real-world setting, particularly given the lack of Therapeutic Goods Authority (TGA) approved
reversal agents available in Australia for apixaban and rivaroxaban. Several observational
studies which have been published since commencement of this research and contribute to the
overall body of knowledge regarding bleeding related ADEs associated with the different
anticoagulants are incorporated in the discussion.

2.3.4.2 Venous thromboembolic events

For the purpose of this thesis, the development of VTE while taking oral anticoagulants
prophylactically or the development of a recurrent VTE while being treated for VTE, will be
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defined as treatment failure. This section of the literature review highlights inconsistent evidence
regarding comparative incidence of recurrent VTE, which by definition for this thesis is referring
to treatment failure.

An annual VTE recurrence rate of between 3-12% has been reported in a systematic review and
meta-analysis which included over 14,000 patients (Rollins et al. 2014). Given that recurrent
VTEs are complications experienced by up to 50% of uncoagulated patients within 10 years after
their first VTE episode (Thachil 2012), this can have important health care cost implications in
Australia, where VTE accounts for 14,000 hospitalisations each year (Clinical Excellence
Commission 2014). It is important therefore, to gain a better understanding about whether or not
anticoagulants, and if possible which types of oral anticoagulants, are a contributing factor to
recurrent VTEs (i.e., treatment failure).

According to data available from the DAEN, a voluntary reporting system established in 1971
(TGA 2017) which includes notifications of mild to severe ADEs that may or may not have
resulted in hospitalisation, anticoagulant-related VTE events occur more commonly with
NOACs compared to warfarin (Department of Health 2019). Records accessed from this
database, between 1 January 1971 to 1 September 2019, suggest that rivaroxaban was
responsible for the largest proportion of PE (4.2%) and DVT (3.7%) reports, followed by
apixaban (PE 2.4%; DVT 2.4%) and then warfarin (PE 0.3%; DVT 0.4%) (Table 3).
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Table 3- Number of reports for DVT and PE while taking anticoagulation 1971-2019
Anticoagulant

Total number of
reports
978

PE
Number of reports
(%)
31 (3.2)

DVT
Number of reports
(%)
28 (2.9)

Rivaroxaban

2123

98 (4.6)

81 (3.8)

Warfarin

2360

8 (0.3)

10 (0.4)

Apixaban

*Data retrieved from DAEN report (Department of Health 2019)

Data available from DAEN, accessed on 1 December 2019, documented unresolved VTE or
VTE recurrence as the second highest reported ADE associated with rivaroxaban use (8.6%),
and the fourth most reported ADE for apixaban (5.7%), in comparison to 1.1% for warfarin
(Department of Health 2019) (Table 4).

Table 4- Number of reports for drug ineffective while taking anticoagulation 1971-2019
Anticoagulant

Total number of
reports
978

Drug ineffective
Number of reports (%)
56 (5.7)

Rivaroxaban

2123

183 (8.6)

Warfarin

2360

27 (1.1)

Apixaban

*Data retrieved from DAEN report (Department of Health 2019)

Although this data provides a foundation of curiosity to warrant further investigation, there are
limitations of this database because the notifications are voluntary. In addition, it needs to be
acknowledged that warfarin had already been used clinically for 17 years, prior to the 2017
establishment of the DAEN database, and that the NOACs have only be available in Australia
since 2013. In other words, the data reported in DAEN, between 1971 and 2019, are potentially
missing 17 years of warfarin related ADEs, only reports on 6 years or less of NOAC related
ADEs, and provides no record of how long the patient was receiving treatment prior to
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experiencing the ADE. Furthermore, there may be a greater interest among clinicians in
reporting ADEs for newer drugs (e.g., NOACs) compared to older drugs (e.g., warfarin),
demonstrated by the paucity of reports regarding warfarin. This also supports the need for
comparative population research.

Focusing on a broader international context, a systematic review and meta-analysis involving 45
randomised controlled trials conducted worldwide with 44,989 patients concluded that there
were no noteworthy differences in rates of recurrent VTEs among patients treated with NOACs
verses those treated with warfarin (Castellucci et al. 2014). These findings were supported by
Van Es et al. (2014) who undertook a meta-analysis of six Phase III clinical trials, including
27,023 patients, which identified non-inferior recurrent VTE outcomes for NOACs (2.0%) and
warfarin (2.2%) (Van Es et al. 2014). Similarly, the AMPLIFY trial, which consisted of 2,609
patients taking apixaban and 2,635 patients taking warfarin, concluded apixaban was noninferior to warfarin in the prevention of recurrent VTEs (RR 0.84, 95% CI -0.60-1.18) (Agnelli
et al. 2013). No difference in recurrent VTEs were also found in the XALIA trial (n=5,142)
which compared the hazard rates or mortality rates for rivaroxaban and warfarin (HR 0.77, 95%
CI 0.40-1.50, P=0.44) (Franchini & Mannucci 2016), and similarly in the EINSTEIN trials
(EINSTEIN DVT investigators 2010; EINSTEIN PE investigators 2012).

A meta-analysis provided evidence of potential limitations to non-inferiority clinical trials when
NOACs are prescribed outside of the strict participant selection criteria, suggesting nonrepresentation of the general population (Burness & Perry 2014). The diversity from these
findings and the suggestion that population-based research may display different results,
identifies the need for further research into ADEs of NOACs compared to warfarin in VTE
treatment and prevention.
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2.3.4.3 Ischaemic stroke

Ischemic stroke accounts for up to 85% of stroke incidence (Milling & Frontera 2017) and based
on randomised clinical trials, NOAC use is associated with similar or reduced risks of stroke
when compared to warfarin and are recommended as first line for stroke prevention in patients
with AF (Gurol 2018). Large-scale Phase III trials for apixaban and rivaroxaban concluded noninferiority for prevention of stroke when compared with warfarin (Brieger et al. 2018). A metaanalysis involving 94,656 participants found a reduction in odds ratio for stroke or systemic
embolism for apixaban of 0.79 (95% CI, 0.66-0.94) and for rivaroxaban of 0.88 (95% CI, 0.741.03) when compared with warfarin (López-López et al. 2017). The ARISTOTLE clinical trial
(n=18,201 participants) found apixaban to be superior in reducing the incidence of stroke
(1.27%) compared to warfarin (1.60%) (Granger et al. 2011). In addition, a longitudinal US
population-based cohort study, including 148,446 participants, found the incidence of ischaemic
stroke, while taking warfarin for AF, to be 4.0% (n=6,006) (Tung et al. 2015), while the
XANTUS trial, one of the first prospective real-world studies for rivaroxaban in AF patients,
concluded that 1.6% (n=6,784) of patients experienced a symptomatic ischaemic stroke
(Kocabas et al. 2016). The evidence of clinical trials and real-world studies supports the benefits
of NOACs compared with warfarin in stroke reduction in AF, although there is a lack of
research into the risk of stroke as an ADE when prescribed oral anticoagulation for any
indication, including VTE treatment and prophylaxis, highlighting the need for additional
research in a real-world setting.
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2.3.5 Contributing factors to ADEs with oral anticoagulants

Several factors can contribute to ADEs with oral anticoagulants including physiological factors,
such as renal impairment (Hillis & Crowther 2014), hepatic impairment (Northup & Caldwell
2013), interactions which include both drug and food interactions (Vandiver et al. 2014),
therapeutic INR control (Nelson et al. 2015) and malignancy (American Society of Clinical
Oncology 2019). Other factors include thrombophilia (Skelley et al. 2017) and individual
patient-related behaviours, such as medication adherence (Scholefield & Wilcken 2017).

For the purpose of this thesis, factors which may contribute to anticoagulant related ADEs that
were investigated included; renal impairment, thrombophilia, medication adherence and
therapeutic INR control. Review of medication errors due to drug interactions were reliant on
accurate and complete medication histories which were not always available and therefore
considered outside the scope of the current research. Hepatic impairment required calculation of
Child-Pugh scores together with a number of biochemistry results which were not available for
all patients and were also considered outside the scope of this study. In addition, individuals with
malignancy were excluded from this study because at the time of designing this study, the
efficacy of NOACs in patients with malignancy was not clearly defined (Sardar et al. 2015) and
because this patient cohort were typically excluded from clinical trials (Agnelli et al. 2013).

2.3.5.1 Renal impairment

The use of oral anticoagulants in patients with renal impairment can be associated with an
increased risk of ADEs and in particular bleeding, making the dosing and selection of
anticoagulants important for this patient group (Hillis & Crowther 2014). The degree of renal
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impairment is often classified according to patients’ creatinine clearance (CrCl), which is a
surrogate measure of renal function (Chin & Doogue 2016). Based on creatinine clearance
values, renal impairment can be categorised as mild (CrCl 25-49mL/min), moderate (CrCl 1024mL/min) or severe (CrCl <10mL/min) (AMH 2018). In current practice, warfarin is not
contraindicated in moderate to severe impairment as doses are titrated to individual patient
responses according to their international normalised ratio (INR), thus warfarin therapy does not
require dose adjustments based specifically on renal impairment (Amin et al. 2017). A US study
which assessed the long-term safety of warfarin in 187 patients (aged less than 50 years to over
70 years) with co-morbidities, including renal impairment, concluded that there were no
significant increase in bleeding for the 23 patients with renal impairment who were on warfarin
(Khan & Datta 2015). Warfarin therefore, remains a well-tolerated anticoagulant for long-term
treatment and prevention of VTE for patients with renal impairment.

Apixaban is contraindicated for use in patients with a CrCl< 25mL/min and rivaroxaban in
patients with a CrCl <30mL/min (AMH 2018; Vandiver et al. 2014) and require calculations of
renal function using the Cockcroft-Gault formula before prescribing this class of oral
anticoagulants (Mekaj et al. 2015). A meta-analysis of eight randomised controlled trials (10,616
participants), was conducted to compare NOACs with warfarin among patients diagnosed with
AF and VTE (Harel et al. 2014). The meta-analysis found NOACs to be non-inferior to warfarin
in the risk of haemorrhage (RR 0.89, 95% CI, 0.68-1.16) or recurrent VTE (RR 0.97, 95% CI,
0.43-2.15) when comparing the safety and efficacy of oral anticoagulation in patients with mild
renal impairment (CrCl 30-50mL/min) (Harel et al. 2014). A recent review of chronic kidney
disease and NOAC use concluded that individuals taking oral anticoagulation with renal
impairment had a higher risk of ischaemic stroke and haemorrhage, compared to individuals
with normal renal function (Heine et al. 2018). Although studies have reported the safe and
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efficacious use of NOACs in mild renal impairment, there is limited evidence to support the safe
use of NOACs in moderate to severe renal failure, especially in a post marketing real-world
setting.

The pharmacokinetics of NOACs suggest that renal impairment decreases the excretion of these
drugs, resulting in increased plasma concentrations (Hillis & Crowther 2014). A review of the
rivaroxaban EINSTEIN trials (8,000 participants), noted that the blood concentration of
rivaroxaban was increased by 1.2 to 1.6-fold in patients with varying levels of renal impairment
(Burness & Perry 2014). These increases in blood concentration would consequently increase
the risk of haemorrhage (Chin & Doogue 2016; Hillis & Crowther 2014). In addition, a recent
real-world observational study for rivaroxaban use in AF noted renal impairment (CrCl<50
mL/min) for 9.4% (638/6784) of participants (Kocabas et al. 2016) and resulted in an increased
proportion of major haemorrhage (1.9%), than previously reported in clinical trials (1.08%)
(Kakkos et al. 2014). Patients with severe renal impairment often have complex comorbidities,
which is why warfarin remains the oral anticoagulant of choice in this patient cohort (Harel et al.
2014; Lutz et al. 2017).

Although NOACs are marketed with the benefits of not requiring the regular monitoring
involved with warfarin, variable dose recommendations based on creatinine clearance are
necessary for the safe use of NOACs. It is important for renal function to be monitored on
initiation of therapy with NOACs, and throughout treatment, to provide dose adjustments as
required. Based on this evidence it was decided to investigate renal function as a potential
contributor to anticoagulant related ADEs in the current study.
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2.3.5.2 Thrombophilia

Thrombophilia is an abnormality of blood coagulation that increases the risk of VTE (Hillis &
Crowther 2014), commonly classified as factor V Leiden, prothrombin gene mutations (Hillis &
Crowther 2014) or antiphospholipid syndrome (APS) (Signorelli et al. 2016). Although
historically treated with warfarin (Skelley et al. 2017), recent evidence suggests that common
thrombophilia are considered to have little influence on recurrent VTE (Stevens et al. 2019).
Based on their pharmacologic activity, NOACs are considered as a potential alternative to
warfarin (Skelley et al. 2017). A meta-analysis of Phase II and Phase III randomised clinical
trials found no significant difference in risk of bleeding or recurrent VTE related ADEs between
individuals with thrombophilia taking NOACs (excluding apixaban) compared to warfarin
(haemorrhage RR 0.92, 95% CI 0.62-1.36; recurrent VTE RR 0.70, 95% CI 0.34-1.44) (Elsebaie
et al. 2019). In contrast to this evidence, a randomised controlled trial in Spain, including 190
patients with antiphospholipid syndrome, concluded significantly more ADEs with rivaroxaban
compared to warfarin, including recurrent VTE (RR 1.83, 95% CI 0.71-4.76) and stroke (RR
19.00, 95% CI 1.12-321.9) (Ordi-Ros et al. 2019). The evidence remains limited and
inconclusive for the use of NOACs in thrombophilia and therefore post-marketing surveillance is
imperative.

2.3.5.3 Medication adherence and INR control

Poor adherence by patients to warfarin as oral anticoagulant therapy is well known to contribute
to poor therapeutic outcomes (Scholefield & Wilcken 2017), with early studies anticipating the
same for rivaroxaban and apixaban (Chin & Doogue 2016; Granger et al. 2011; Harel et al.
2014). Based on the findings of an Australian study, between 30-60% of patients are non-
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adherent to prescribed medications (Leung et al. 2017). It is important therefore, to consider that
poor medication adherence can affect therapeutic responses to anticoagulant therapy, including
NOACS with their much shorter half-lives as compared to warfarin.

Studies conducted in the UK and US suggest that adherence to warfarin therapy varies from 4060% (Kearon et al. 2016; Thachil 2012). Warfarin therapy requires regular monitoring until a
therapeutic INR is achieved. Monitoring is an invasive and complicated process, which is further
complicated in the treatment of VTE as the patient requires short-term co-administration of
injectable anticoagulant on initiation of therapy (Hillis & Crowther 2014). During this time, dose
adjustments to warfarin are made and regular haematological monitoring is required until
therapeutic levels are achieved. Certainly, the requirement for regular blood tests and
appointments associated with warfarin therapy can be a risk to adherence and a deterrent for
many patients (Vandiver et al. 2014). However, it can also be perceived as an advantage of
warfarin therapy because the INR not only assures therapeutic levels are reached, but it can also
be an opportunity to monitor for adherence (Nelson et al. 2015).

Time spent in therapeutic range for warfarin therapy is important to avoid treatment failure. A
US study reviewed INR levels for 9,433 patients taking warfarin to investigate the amount of
time spent in the therapeutic range, between 2 and 3. In this study, approximately two-thirds
(67%) of warfarin levels for participants were in the therapeutic range, with 23% being
subtherapeutic and approximately 16% experiencing supratherapeutic INR values (>3.0) (Nelson
et al. 2015). In this same study, at subtherapeutic levels, warfarin was less effective for the
treatment and prevention of VTE and at supratherapeutic levels patients were at risk of
experiencing haemorrhagic ADEs. It is possible that poor adherence to warfarin therapy
contributed to time spent outside of therapeutic range, as suggested by the results of a
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retrospective US study of 1,753 patients, mean age 58 years, which found that poor adherence to
warfarin resulted in increased VTE recurrence among 7.6% (n=137) of patients, with
subtherapeutic INR (<2.0) (RR 3.37, 95% CI, 2.16–5.27 per 100 person-years) (Nordstrom et al.
2015).

The EINSTEIN trials documented improved patient satisfaction with rivaroxaban compared with
warfarin and suggested better medication adherence with NOACs would reduce the incidence of
recurrent VTE (Toth 2016). This notion of improved medication adherence for rivaroxaban was
not supported by a Canadian study of 26,000 patients, which found that 32% of patients
prescribed rivaroxaban stopped taking the medication for at least two weeks within the first six
months of treatment (Scholefield & Wilcken 2017) and a meta-analysis comprising 1.6 million
patients taking NOACs for AF concluded 75.6% adherence (Shehab et al. 2019). These poor
adherence rates are a concern because, unlike warfarin, there is no recommended routine
haematological monitoring to determine therapeutic levels. Despite this, NOACs are considered
a desirable treatment option for many patients (Chin & Doogue 2016). A lack of adherence
however, can be especially problematic because NOACs have a fast onset and offset of action
(eMIMS 2016), so if a single dose is missed, this could result in sub-therapeutic drug levels and
predispose patients to a higher risk of ADEs, including thromboembolic events (Chin & Doogue
2016; Vandiver et al. 2014). In addition, an Australian patient survey acknowledged that 45.1%
(n=386) of individuals prescribed NOACs for AF did not have a high level of adherence
(Obamiro et al. 2018). The findings from this study concluded that the younger cohort, up to 65
years old, were less likely to have high adherence compared to individuals over 65 years (OR
0.54, 95% CI 0.33-0.88, P = 0.013) and females demonstrated higher adherence compared to
males (OR 1.69, 95% CI 1.08-2.64, P = 0.023).
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Regular monitoring and health professional contact have demonstrated a positive effect on
medication adherence to warfarin (Nelson et al. 2015). Considering NOACs are recommended
first line in VTE (Tran et al. 2019) with a fast offset of action and lack of regular monitoring,
adherence is imperative for efficacy of treatment and reasons for lack of adherence need to be
further investigated. There are currently no reported studies that focus on adherence in patients
receiving oral anticoagulants for VTE treatment and prevention, highlighting the need for further
research into factors affecting patient adherence to oral anticoagulants. If patient adherence is
identified as a problem then the ability to monitor INR levels may make warfarin a preferable
oral anticoagulant.

2.4 Conclusion
Based on the articles included in this review there are a number of gaps that exist in current
literature. These relate to the many factors which may contribute to oral anticoagulant-related
ADEs and factors that can impact on therapeutic response. It is therefore important that future
research, such as the research included in the current thesis which investigates these factors, and
compares their impact on NOACs and warfarin in a post-marketing real-world setting.
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3. METHODOLOGICAL APPROACH

This chapter will provide an overview of the methodological approach used in this thesis. The
research philosophy of pragmatism (Saunders et al. 2012) was used to evaluate the hypotheses
through application of quantitative and a pilot study of patients with recurrent VTE. The blend of
statistical testing of the hypotheses, while incorporating human interest, is imperative when
researching the topic of medication management (Gray 2014). This approach to research is
common among health researchers (Tariq & Woodman 2013) who use it to provide meaningful
findings which are relevant and translatable to clinical practice.

The research incorporated two separate studies.
Study 1 was a retrospective observational cohort study to assess rates of ADEs among people
prescribed oral anticoagulants (both warfarin and NOACs) for any indication and to identify
potential contributing factors including renal function. Study 2 was a prospective study including
patient interviews which assessed the effect of medication knowledge and adherence on
recurrent VTE among people taking NOACs. The interview included four open-ended questions
in combination with a validated medication knowledge tool (Obamiro et al. 2016) and
medication adherence questionnaire (Morisky et al. 1986). Table 5 provides a brief overview of
the two separate studies.
Table 5- Research summary
Study
1. Quantitative
retrospective
observational cohort
study of
hospitalisations
2. Patient interview,
knowledge tool and
adherence
questionnaire

Aim
To quantify the rate of hospitalisation
relating to ADEs while taking an oral
anticoagulant for any indication and
potential contributing factors

Method of analysis
Descriptive and
inferential statistical
analysis and
significance testing

To explore patient knowledge and
adherence as contributing factors to
recurrent VTE among patients
prescribed NOACs

Descriptive statistical
analysis
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3.1 Setting

The population of interest in both studies were residents from the Illawarra Shoalhaven area, the
third-largest regional economy in New South Wales, Australia (NSW Government 2018). The
Australian Bureau of Statistics use a geographic framework, the Australian Statistical Geography
Standard, to publish geographically-standardised statistics. The current standard includes a
Statistical Area (SA) hierarchy, at levels SA1 through SA4, of which level SA3 is designed for
output of regional data (Australian Bureau of Statistics 2018). Australia is divided into 358
standardised regional areas (defined as SA3 regions), each with a population of between 30,000
and 130,000 people (Australian Bureau of Statistics 2016). The studies include residents from
four SA3’s in the Illawarra region (10701: Dapto - Port Kembla, 10702: Illawarra Catchment
Reserve, 10703: Kiama – Shellharbour, and 10704: Wollongong) and one SA3 in the
Shoalhaven region (11401: Shoalhaven) depicted in Figure 3. The Australian Bureau of
Statistics National Census of Population and Housing figures for residents, aged 18 years and
over, at 9 August 2016 was estimated to be 228,808 (Australian Bureau of Statistics 20152017a) for the Illawarra region and 79,848 for the Shoalhaven region (Australian Bureau of
Statistics 2015-2017b).
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Figure 3- Illawarra and Shoalhaven census region by geographical area (Australian
Bureau of Statistics 2015-2017a, 2015-2017b)
Study 1, included a retrospective analysis of hospitalisations during the financial years 2015 to
2017, for Illawarra Shoalhaven residents, aged 18 years and over, who presented to one of the
nine Illawarra Shoalhaven Local Health District (ISLHD) hospitals: Coledale, Bulli,
Wollongong, Port Kembla, Shellharbour, Kiama, David Berry, Shoalhaven and MiltonUlladulla, shown in Figure 4.

Figure 4- Hospital locations for ISLHD
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The participants included in Study 2, were aged 18 years and over, that had attended the
Vascular Care Centre outpatient clinic in Wollongong, NSW, between 1 May 2018 and 28
February 2019. The Vascular Care Centre is a private clinic, there are no public facilities run by
the Illawarra Local Health District for vascular patients in NSW, except for diabetic foot clinics.
All patients are referred to private rooms run by vascular surgeons.

3.2 Study 1

Study 1 was a retrospective cohort study undertaken in two stages (Figure 5). Stage 1 identified
the study cohort, which included individuals prescribed apixaban, rivaroxaban or warfarin on
one or more occasions in the Illawarra and Shoalhaven region. Stage 2 identified the hospitalised
cohort, which included individuals hospitalised in the ISLHD for an ADE related to taking
apixaban, rivaroxaban or warfarin.

Stage 1
Study cohort
Individuals prescribed
oral anticoagulants for
financial years 2015/16
and 2016/17 for the
Illawarra and
Shoalhaven regions

Stage 2
Hospitalised cohort
Individuals hospitalised
for ADEs associated
with oral anticoagulant
in ISLHD for financial
years 2015/16 and
2016/17

Figure 5- Study 1 stages
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3.2.1 Stage 1- Study cohort

3.2.1.1 Study population

Stage 1 utilised PBS data obtained from the Department of Human Services Australia which
provided information regarding subsidised medicines dispensed in Australia (Paige et al. 2015).
The data included aggregated PBS prescription data about Illawarra and Shoalhaven residents,
aged 18 and over, who had been dispensed one or more prescriptions for the oral anticoagulants,
apixaban, rivaroxaban or warfarin, in each of the financial years 2015/16 and 2016/17, and
across both financial years, based on date of dispensing and patient age at the end of each
financial year. Switching between oral anticoagulant therapies is common practice (Hellfritzsch
et al. 2016). For example, a Spanish study found 18.6% (n= 176/946) of patients with AF, who
were prescribed warfarin, switched to NOAC therapy within 12 months of a prescription
(Rivera-Caravaca et al. 2018). Without unit record data, the dates of any switching could not be
quantified in this study. To ensure the size of the population at risk, was estimated as accurately
as possible using aggregate data, the PBS request included information separately by financial
year on the number of persons prescribed each NOAC individually, number prescribed any
NOAC (apixaban or rivaroxaban) and number prescribed any anticoagulant (apixaban,
rivaroxaban or warfarin). Patients who did not switch medications were therefore considered in
the population at risk (denominator of hospitalisation rate) in each year they were dispensed that
medication. Patients who switched medications (for example dispensed a NOAC and dispensed
warfarin within a financial year), were counted in the population at risk of hospitalisation
(denominator) for each drug for that year. Any hospitalisations were attributed in the
hospitalisation rate (numerator of hospitalisation rate) for the drug which was being taken when
hospitalised.
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ADEs can occur within one month of initiation of treatment with an oral anticoagulant (Chen et
al. 2016; McIlroy et al. 2018). The decision to include PBS data, based on a single supply, was
to help capture every ADE resulting in hospitalisation while taking an oral anticoagulant. Unit
record data would have provided information on the persistence of use of each medication,
however because this level of data was costly and required long lead times to obtain, it was
considered outside the scope of funding for this thesis.

Data were not obtained for dabigatran because although it is approved for use in Australia, it was
not subsidised by PBS for VTE during the study period. The PBS item codes for OACs available
from Services Australia, listed in Table 6, combine VTE and AF indications under the same item
code. For this reason, individuals prescribed apixaban, rivaroxaban or warfarin for AF were
included in this research.

Table 6- PBS item codes for oral anticoagulants
PBS codes by indication
VTE treatment and/or prevention

apixaban
10414D

rivaroxaban
2160Q

5061J
VTE prophylaxis (hip and knee surgery)

warfarin
02843P
02290G

5054B

9467G

02844Q

5500L

9466F

02211J

9465E
9469J
9468H
VTE or AF

02735Y

2268J

02744K
AF

*

02691P

* PBS item codes combine VTE and AF indications under the same item code.
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3.2.1.2 Data analysis

Descriptive statistical analysis was used to describe characteristics and prevalence rates
calculated for Illawarra Shoalhaven individuals prescribed apixaban, rivaroxaban or warfarin
across the study period:
•

Prevalence of apixaban, rivaroxaban and warfarin prescribed by sex, age and geographic
region.

•

Prescription data by drug and by financial year.

All statistical analyses were conducted using IBM Statistical Package for the Social Sciences
(SPSS) version 26 (Murali 2019).

3.2.2 Stage 2- Hospitalised cohort

3.2.2.1 Study population

The hospitalised cohort for Stage 2 were identified through a complex data extraction process
and review of electronic medical records for patients who had been hospitalised in the ISLHD
with a primary or secondary diagnosis of VTE, stroke or haemorrhage, while prescribed
apixaban, rivaroxaban or warfarin.

Patient data for Stage 2 were extracted from the Illawarra Health Information Platform (IHIP), a
sophisticated non-identifiable data platform (University of Wollongong 2019). The extracted
data included hospitalisations at ISLHD facilities, during financial years 2015/16-2016/17, with
a primary or secondary diagnosis of VTE, haemorrhage or stroke, and hospitalisations for long
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term oral anticoagulant use or anticoagulants causing ADEs in therapeutic use. Haemorrhagic
events were categorised as either CRNMB (minor) or major haemorrhagic events as per the
International Society of Thrombosis and Haemostasis definitions (International Society of
Thromobosis and Haemostasis 2015). CRNMB was classified as a minor GI haemorrhage, such
as epistaxis, haemoptysis, haematuria or other minor haemorrhage (Kaatz et al. 2015). Major
haemorrhage was characterised as haemorrhage into a critical site or a haemorrhage which
required a blood transfusions (Kaatz et al. 2015). VTE ADEs included the first incidence of
DVT and PE while taking an oral anticoagulant for any indication. Recurrent VTE was classified
as a subsequent DVT or PE while taking oral anticoagulation. Ischaemic stroke ADEs were
identified as transient ischaemic attacks or cerebral infarcts.

ED presentations were extracted based on visit date and hospital admissions based on date of
discharge. Diagnosis information was extracted using ICD-10-AM (9th edition) codes
(Weatherspoon & Chattopadhyay 2013) for admitted patients and Systematized Nomenclature of
Medicine- Clinical Terms (SNOMED CT) codes (Department of Health 2008) for ED
presentations (Table 7).
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Table 7- ICD-10-AM (9th edition) and SNOMED codes for DVT, PE, haemorrhage, stroke
and circulating anticoagulant
ICD-10-AM (9th edition) codes for
haemorrhagic disorders and stroke
D68.3- haemorrhagic disorders due to
circulating anticoagulants
R58- haemorrhage, not elsewhere classified
K62.5- haemorrhage sphincter
K13.7- haemorrhage mouth
K22.8- haemorrhage oesophagus
N32.8- haemorrhage bladder
N39.9 haemorrhage uterine
K92- haemorrhage bowel/stomach
I60; I61; I62- haemorrhagic stroke
I64- ischaemic stroke
K25; K26; K27; K28; K29- gastro
haemorrhage
D62; J94.2; H113; H35.6; H43.1; N02; N95;
R04- extracranial bleeding
R31- unspecified haematuria
ICD-10-AM (9th edition) codes for VTE
I82.0 – Budd-Chiari Syndrome
I82.1 – Thrombophlebitis migrans
I82.2 – Embolism and thrombosis of Vena
Cava
I82.8 – Embolism and thrombosis of other
specified veins
I82.9 – Embolism and thrombosis of
unspecified vein
I80; I81.9
I26.0 – Pulmonary embolism with mention of
acute cor pulmonale
I26.9 – Pulmonary embolism without mention
of acute cor pulmonale
I74- systemic embolism
ICD-10-AM (9th edition) codes for other
Z92.1 long term anticoagulant use
Y44.2; Y44.3- anticoagulants causing ADEs
D68.5- primary thrombophilia
D68.6- other thrombophilia

SNOMED codes for haemorrhagic
disorders and stroke
191287000 - Haemorrhagic disorder due to
circulating anticoagulant
64779008- blood coagulation disorder
75038005- cerebellar haemorrhage
274100004- cerebral haemorrhage
195176009- subdural haemorrhage
95453001- subdural haematoma
1386000- intracranial haemorrhage
22490002- bleeding mouth
1770902- bleeding oesophageal
422504002- ischaemic stroke
86276007- bleeding gums
74474003- gastro haemorrhage
266464001- haemorrhage rectum
12063002- haemorrhage rectal
197887003- haemorrhage bladder
SNOMED codes for VTE
82385007- Budd-Chiara
128053003- Deep vein thrombosis
1748006- Thrombophlebitis of deep vein
63363004- Superior vena cava syndrome
371039008- Thromboembolic disorder
42909802- Thromboembolism of vein
234049002- Venous embolism
111293003- Venous thrombosis
309735004- Thrombosis lower limb
59282003- Pulmonary embolism
706870000- Acute PE
713078005- PE on long-term anticoagulation
74315008- Pulmonary microemboli
233925004- Pulmonary thromboembolism

After data extraction from IHIP, the pharmacist investigator (and Masters’ candidate) undertook
a series of additional steps (Figure 6) to identify the hospitalised cohort (Stage 2 cohort) who had
experienced an ADE, while prescribed apixaban, rivaroxaban or warfarin at time of presentation
or admission to hospital.
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Figure 6- Flow diagram for IHIP data extraction process and participant identification

Patients needed to be residents of the Illawarra and Shoalhaven and aged 18 years and over for
inclusion into the hospitalised cohort (Stage 2). Non-residents of the Illawarra and Shoalhaven
were excluded. This research focused on unique ADEs and not on re-presentation to hospital for
poor management of an ADE. This decision was made because of the evidence, primarily from
the US, that approximately 17.9% of patients re-present to hospital at least once within 28 days
of starting warfarin therapy due to poor management (Hamar et al. 2018). Hence intra-hospital
transfers and re-presentation to hospital within 28 days were excluded from Stage 2. Other
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exclusions for Stage 2 included non-spontaneous events which were deemed to be expected side
effects while taking oral anticoagulation therapy. For example, bruising following a fall or
bleeding following procedures, such as a tooth extraction or colonoscopy. The rationale for these
exclusions, were to explore spontaneous ADEs (Chen et al. 2016; Sembill et al. 2019) focusing
on rates of ADEs and factors which contribute to intrinsically preventable ADEs, rather than
external factors which could contribute to ADEs. In addition, malignancy was another exclusion
criteria for stage 2 because of the evidence that malignancy significantly increases the
pathophysiological risk of recurrent VTE by 13.2% (Thachil 2012) (Table 8).

Table 8- Study 1 Stage 2 inclusion and exclusion criteria
Inclusion criteria
• Resident Illawarra or Shoalhaven
•

18 years and older

•

Hospitalisation for haemorrhage
while taking apixaban, rivaroxaban

•

Exclusion criteria
• Under 18 years
•

within 28 days of discharge
•

within 24 hours following tooth

Hospitalisation for VTE while

extraction
•

warfarin

Hospitalisation for haemorrhage
following a mechanical fall

Hospitalisation for ischaemic stroke

•

Hospitalisation for malignancy

while taking apixaban, rivaroxaban

•

Hospitalisation for post colonoscopy

or warfarin
•

Hospitalisation for haemorrhage

or warfarin
taking apixaban, rivaroxaban or
•

Re-presentations or readmissions

Re-presentations or readmissions

bleed
•

Intra-hospital transfers

after 28 days
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3.2.2.2 Data analysis

Analysis for Stage 2 (hospitalised cohort) was conducted to investigate variance in demographic
and clinical groups for patients presenting or admitted to ISLHD for ADEs by each financial
year (2015/2016 and 2016/2017) and as combined years (2015-2017).

Descriptive analyses (counts, means and percentages) were used to describe hospitalisations for
ADEs among persons prescribed oral anticoagulants. The following patient subgroups were
investigated to identify differences between oral anticoagulant ADEs:
•

region of residence (Illawarra and Shoalhaven)

•

type of hospitalisation (ED/admitted)

•

sex

•

age

•

length of stay (LOS)

•

potential contributing factors, including renal function, indication, comorbidities and INR

Combined aggregated PBS data from Stage 1, and hospitalisation data from Stage 2, enabled
estimation of rates of hospitalisations. Oral anticoagulant prescribing rates and ADE incidence
rates were calculated using the mean of the rates at which unique individuals were prescribed
each oral anticoagulant for each year, and are expressed as rates per 1,000 people prescribed per
year. The following health service utilisation measures were used to investigate the ADEs for
each oral anticoagulant:
•

total hospitalisations

•

hospitalisations by financial year
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•

type of hospitalisation (ED versus admission)

•

haemorrhagic events

•

VTE events for all indications

•

ischaemic stroke events for all indications

The relative risk (RR) was calculated for the outcomes of ADEs for each oral anticoagulant in
terms of VTE, haemorrhage and ischaemic stroke. The confidence interval (CI) used to quantify
the uncertainty associated with estimates were calculated at the 95% level. Multivariate logistic
regression analysis (Petrie & Sabin 2009) was used to model the probability of hospitalisation
for ADEs (haemorrhage, VTE or ischaemic stroke), among residents taking each oral
anticoagulant. The logistic regression model was used to estimate an unadjusted odds ratio (OR)
for hospitalisation for an ADE among those taking NOACS compared to warfarin, then among
those taking rivaroxaban compared to those taking apixaban. The model was then used to
calculate an adjusted odds ratio (aOR) accounting for all covariates, sex, age and geographic
region, which were all potential contributing factors for ADEs. No threshold for model entry was
applied to ensure the model for each oral anticoagulant was adjusted for the same set of factors.
Variance inflation factors were calculated to assess for multicollinearity between independent
variables in the regression model.
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3.3 Study 2

Poor medication adherence and limited health literacy has been associated with inadequate
anticoagulant control (Rolls et al. 2016). The second study was a small-scale pilot investigation
into whether poor oral anticoagulant medication knowledge, understanding and adherence were
present among those with recurrent VTE, whilst being prescribed a NOAC (apixaban or
rivaroxaban) for treatment of VTE. The study consisted of patient interviews, which used a
combination of four open-ended interview questions (Appendix 1) and the
•

Anticoagulation Knowledge Tool - a validated 20-item medication knowledge tool
(Obamiro et al. 2016), and

•

Morisky, Green, and Levine (MGL) Adherence Scale, also known as the MAQ
(Medication Assessment Questionnaire) (Morisky et al. 1986) a four-item Medication
Adherence Questionnaire.

Permissions were granted by the authors of the Anticoagulation Knowledge Tool and Morisky
Medication Adherence Questionnaire (Appendix 2) to use these tools as part of the study. The
20-minute interviews were conducted by the pharmacist researcher (Masters' candidate) for
patients who had experienced a recurrent VTE, whilst prescribed a NOAC to treat a previous
VTE and attended the Outpatient Vascular Care Centre, Wollongong between May 2018 and
February 2019. These two stages of Study 2 are depicted in Figure 7.

Participant recruitment
Patients that attended the Vascular
Care Centre for recurrent VTE while
prescribed apixaban or rivaroxaban

Patient interviews

Figure 7- Study 2 design
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3.3.1 Participants

Participants were eligible for Study 2, if they were residents of the Illawarra and Shoalhaven,
aged 18 years and over, and attended the Vascular Care Centre (Vascular Outpatient Clinic
Cohort) for recurrent VTE while prescribed apixaban or rivaroxaban. Participants were required
to be English speaking, because data collection tools were only available in English and the
project budget did not include interpreter services. Eligible participants were required to have no
documented cognitive impairment. More detailed inclusion and exclusion criteria for Study 2
participants are described in Table 9.

Table 9- Study 2 inclusion and exclusion criteria
Inclusion criteria
• Resident Illawarra or Shoalhaven

Exclusion criteria
• Non-resident of Illawarra or

•

18 years and older

•

Attended vascular clinic for

•

Under 18 years

recurrent VTE whilst taking

•

Attended vascular clinic for recurrent

•

Shoalhaven

apixaban or rivaroxaban for VTE

VTE whilst prescribed other

English speaking

anticoagulation
•

Documented cognitive impairment

All eligible patients that attended the Vascular Care Centre for review of a recurrent VTE, while
taking apixaban or rivaroxaban, were invited to participate in the study and provided with the
Patient Information Sheet (Appendix 3) and invited to complete the Patient Consent form
(Appendix 4) during their attendance to the centre. The receptionist at the Vascular Care Centre
provided invitations to all eligible patients. The receptionist was blinded to the aims of the study
in order to eliminate any chance of selection bias by the pharmacist researcher (Masters’
candidate). The consent form provided contact information for the pharmacist researcher to call
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and make an appointment for the telephone interview at a time which was convenient to the
participant.

3.3.2 Data collection

An interview guide (Appendix 1) was used to structure the collection of data. Each telephone
interview took an average of 20 minutes. The open-ended interview questions were primarily
used to collect information about why the participant had attended the vascular clinic and to
obtain a self-reported medical and medication history, while the medication knowledge tool
(Obamiro et al. 2016) was used to collect information about the participant’s knowledge about
the mechanism of action of the NOAC, why it was important to take the medication, and the
consequences of missing doses or possible side effects. The medication adherence questionnaire
(Morisky et al. 1986) was used to collect information about participant anticoagulant medication
adherence behaviours.

Each of the interviews were recorded on a digital audio recorder and transcribed verbatim.
Results for the medication knowledge and adherence questionnaire were recorded as hard copies
for each participant.

3.3.3 Data analysis

Descriptive statistical analyses were conducted on the scores obtained from participants’
completion of the validated anticoagulant medication knowledge tool (Obamiro et al. 2016). The
knowledge tool was scored using a dichotomous scale with a score of ‘1’ for each correct or ‘0’
for an incorrect answer (Obamiro et al. 2016). A total of 20 questions were included, with
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additional scores obtainable for question 4 regarding how the medicines are taken, question 6
about why it is important to take the medicine exactly as prescribed by the doctor and questions
18 and 19, which asks for three signs of side effect and three ways to reduce side effects
(Appendix 3). The maximum score achievable, according to the validated tool, was 25, where
the final scores were presented as a percentage of correct answers.

Descriptive analysis was also used to investigate if medication adherence to NOACs, using the
Morisky Medication Adherence Questionnaire (Morisky et al. 1986), was a contributor to
recurrent VTE among the study participants . The questionnaire was scored using a dichotomous
scale, answers of no scored ‘1’ and yes scored ‘0’. The maximum score achievable according to
the Morisky scale was ‘4’. The final scores were rated from lowest adherence ‘1’ to highest
adherence ‘4’ (Morisky et al. 1986).

3.4 Ethical considerations

Ethical approval to undertake Studies 1 and 2 were obtained from the combined University of
Wollongong and ISLHD Human Research Ethics Committee, approval number 2017/493
(Appendix 5). A Site-Specific Approval (SSA) was obtained to enable ethical research to be
conducted within ISLHD (Appendix 6).

Study 1 attained a waiver of patient consent from the ethics committee as a result of the large
cohort. It was estimated that 5,000 hospitalisations would be included in the two-year
retrospective study. This estimate was calculated from the number of hospitalisations attributed
to haemorrhage or VTE as a principal or secondary diagnosis across the ISLHD.
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A key ethical requirement for Study 2 of the research was to ensure that it was clearly
communicated to participants that they could refuse or withdraw consent at any time, without
affecting their relationship or treatment with healthcare professionals.
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4. FINDINGS

The findings for Study 1 and Study 2 are reported in detail below.

4.1 Study 1

This section will report on the findings from Study 1 of the research, based on the two stages
described in the study design (Chapter 3).

4.1.1 Stage 1- Study cohort

4.1.1.1 Population cohort demographics

The estimated residential population was 308,656 individuals, aged 18 years and over, for the
four Illawarra SA3 regions (which accounted for 74.1% of the population cohort) and the one
Shoalhaven SA3 region (25.9% of the population cohort) (Australian Bureau of Statistics 2016).
The population cohort was 48.7% male and 51.3% female, and 74.5% of the population were
aged under 65 years.

4.1.1.2 Study cohort demographics

According to the PBS data, 11,259 residents received one or more prescriptions for apixaban,
rivaroxaban or warfarin in 2015/16, and 12,171 residents in 2016/17 (Table 10). The mean
number of residents receiving one or more prescriptions for these oral anticoagulants per year
was 11,715, or 3.8% (11,715/308,656) of the Illawarra and Shoalhaven population.
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Males were prescribed oral anticoagulants at a higher rate than females, at 42.0 per 1,000 males
per year, compared to 34.1 per 1,000 females per year (P<0.001, 95% CI 1.13-1.35) (Table 10).
Prescribing rates of anticoagulants increased with age. Individuals aged under 65 years were
prescribed oral anticoagulants at a rate of 9.6 per 1,000 people per year and individuals aged 8084 years at a prescribing rate of 192.6 per 1,000 persons per year. Individuals from the Illawarra
region had a lower oral anticoagulant prescribing rate 36.3 per 1,000 persons per year than
Shoalhaven residents 42.6 per 1,000 persons per year (P<0.001, 95% CI 0.78-0.93).

Table 10- Study cohort population prescribing rates by demographics, 2015/16-2016/17
Study cohort
(Persons prescribed oral
anticoagulants per year)
Mean of
2015/16
2015/16 2016/17
and 2016/17
N b (%)

Illawarra Shoalhaven populationa
Illawarra/
Population
Shoalhaven prescribed oral Prescribing rates
Population anticoagulantsc per 1,000 per year
N (%)
%

Sex
Male

6,057

6,585

6,321 (54.0)

150,402 (48.7)

4.2

42.0

Female

5,202

5,586

5,394 (46.0)

158,254 (51.3)

3.4

34.1

<65

2,163

2,270

2,217 (18.9)

229,906 (74.5)

1.0

9.6

65-69

1,410

1,515

1,463 (12.5)

23,942 (7.8)

6.1

61.1

70-74

1,754

1,971

1,863 (15.9)

19,041 (6.2)

9.8

97.8

75-79

2,145

2,200

2,173 (18.5)

14,710 (4.8)

14.8

147.7

80-84

1,943

2,126

2,035 (17.4)

10,564 (3.4)

19.3

192.6

85+

1,844

2,089

1,967 (16.8)

10,493 (3.4)

18.7

187.4

Illawarra

7,974

8,652

8,313 (71.0)

228,808 (74.1)

3.6

36.3

Shoalhaven

3,285

3,519

3,402 (29.0)

79,848 (25.9)

4.3

42.6

11,259

12,171

11,715

308,656

3.8

38.0

Age

Region

Total
a.
b.
c.

Population aged 18 years and over
The yearly counts are the mean of the counts from 2015/16 and 2016/17
The mean prescribing rate across the two years in the study (e.g., for males: % prescribed =
6321/150,402*100)
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4.1.1.3 Oral anticoagulant prescriptions by year and demographics

Prescribing rates by year

Using the PBS data extracted for the two-year study period at least one prescription was
dispensed to individuals, aged 18 years and over, as follows:
•

Apixaban: 2,038 persons in 2015/16 and 3,125 in 2016/17, mean of 2,582 per year.

•

Rivaroxaban: 3,809 persons in 2015/16 and 4,371 in 2016/17, mean of 4,090 per year.

•

NOAC total: 5,794 persons in 2015/16 and 7,369 in 2016/17, mean of 6,582 per year.

•

Warfarin: 5,912 persons in 2015/16 and 5,178 in 2016/17, mean of 5,545 per year.

•

NOAC or warfarin total: 11,259 in 2015/16 and 12,171 in 2016/17, mean of 11,715 per
year.

To quantify the PBS data for individuals dispensed at least one prescription, which does not
account for switching of oral anticoagulant treatment within a financial year, the mean number
of individuals dispensed NOACs and/or warfarin was 12,171, compared to 11,715 individuals
dispensed either NOACs or warfarin. The mean number of individuals that switched their oral
anticoagulant treatment from NOACs to warfarin, or vice versa, during 2015/16 and 2016/17
was 412.

Between 2015/16 and 2016/17 prescribing rates (residents with one or more prescription) for
NOACs (apixaban or rivaroxaban) increased from 18.8 per 1,000 population per year to 23.9 per
1,000 population per year (P<0.001, 95% CI 1.27-1.28). This contrasted with a decrease in the

number of residents with one or more prescriptions for warfarin, from 19.2 per 1,000 population
to 16.8 per 1,000 population per year (P<0.001, 95% CI 0.87-0.88) (Figure 8). During the same
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period, prescribing rates for apixaban increased from 2,038 per 1,000 per year to 3,125 per 1,000
population per year (53.3% increase) and rivaroxaban prescribing rates increased from 3,809 per
1,000 population per year to 4,371 per 1,000 population per year (14.8% increase).

NOACs

Prescribed rate per 1000 people

25.0

warfarin

20.0

15.0

10.0

5.0

0.0
2015/16

2016/17

Figure 8- Study cohort prescribing rate for NOACs and warfarin by financial year

Prescribing rates by sex

Table 11 shows prescription rates by sex and by oral anticoagulant. Higher prescribing rates
were apparent for NOACs compared to warfarin, for both males and for females. Among males,
NOACs were prescribed for 23.4 per 1,000 population per year compared to warfarin which was
prescribed for 20.0 per 1,000 population per year (P<0.001, 95% CI 1.07-1.28). Among females,
NOACs were prescribed for 19.3 per 1,000 population per year, compared to warfarin at 16.0
per 1,000 population per year (P<0.001, 95% CI 1.10-1.32).
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Table 11- Study cohort prescribing rate by oral anticoagulant and sex, 2015/16-2016/17
Illawarra/
Shoalhaven
Population
N

Apixaban

Rivaroxaban

NOACs

Warfarin

N a (Rate/
1,000/year)
2,195 (14.6)

N b (Rate/
1,000/year)
3,524 (23.4)

N a (Rate/
1,000/year)
3,009 (20.0)

Male

150,402

N a (Rate/
1,000/year)
1,370 (9.1)

Female

158,254

1,212 (7.7)

1,895 (12.0)

3,058 (19.3)

2,537 (16.0)

Total

308,656

2,582 (8.4)

4,090 (13.3)

6,582 (21.3)

5,545 (18.0)

Sex

a.
b.
c.

The prescribing rate is the average of the rates from 2015/16 and 2016/17.
Counts of people prescribed each NOAC do not add to the total counts for all NOAC due to some people
being prescribed more than one type of NOAC during the 2-year study period.
Counts of people prescribed each oral anticoagulant do not add to the total counts for all oral
anticoagulants due to some people being prescribed more than one type of NOAC or warfarin during the
2-year study period

Prescribing rates by age

Prescribing rates increased with age for both NOACs and warfarin. NOAC prescribing rates
were higher than for warfarin in the younger age groups (Figure 9); for example, for the under
65-year age group (NOAC 6.9 per 1,000 population per year, warfarin 2.9 per 1,000 population
per year, P<0.001, 95% CI 2.18-2.60). Warfarin was the most prescribed anticoagulant in
persons aged over 80 years (including 80-84 and 85+), 115.6 per 1,000 population per year
compared to 79.1 per 1,000 population per year prescribed NOACs (P<0.001, 95% CI 1.341.60).
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NOACs

<65

warfarin

Age group

65-59

70-74

75-79

80-84

85+
0

20

Illawarra/
Shoalhaven
Population
N

40

60

80

100

Prescribing rates by oral anticoagulant
Apixaban
Rivaroxaban
NOACs

120

140

Warfarin

229,906

Na
(Rate/1,000/
year)
447 (1.9)

Na
(Rate/1,000/
year)
1106 (4.8)

Nb
(Rate/1,000/
year)
1576 (6.9)

Na
(Rate/1,000/
year)
670 (2.9)

65-69

23,942

363 (15.2)

582 (24.3)

925 (38.6)

589 (24.6)

70-74

19,041

428 (22.5)

687 (36.1)

1,097 (57.6)

840 (44.1)

75-79

14,710

480 (32.6)

723 (49.1)

1,172 (79.6)

1,093 (74.3)

80-84

10,564

449 (42.5)

557 (52.7)

981 (92.9)

1,140 (107.9)

85+

10,493

415 (39.6)

435 (41.4)

831 (79.2)

1213(115.6)

Age
<65

a.
b.

The yearly rate is the average of the rates from 2015/16 and 2016/17
Counts of persons prescribed each NOAC do not add to the total counts for all NOAC due to some
people prescribed more than one NOAC during the 2-year study period, and due to small cells being
withheld for some age group by oral anticoagulant by region combinations in the aggregate PBS data.

Figure 9- Study cohort prescribing rates by oral anticoagulant and age, 2015/16-2016/17
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Prescribing rates by region

Overall, prescribing rates for oral anticoagulants were higher in the Shoalhaven region compared
to the Illawarra region (Table 12). This pattern was consistent for NOACs, 22.8 per 1,000
population per year in Shoalhaven, compared to 20.8 per 1,000 population per year in the
Illawarra (P=0.040, 95% CI 1.00-1.20), and for warfarin 21.1 per 1,000 population per year in
Shoalhaven compared to 16.9 per 1,000 population per year in the Illawarra (P<0.001, 95% CI
1.14-1.36). The pattern of rivaroxaban prescribing by region was similar to the trend mentioned
above, with Shoalhaven residents prescribed a rate of 15.7 per 1,000 population per year,
compared to the Illawarra 12.4 per 1,000 population per year (P<0.001, 95% CI 1.16-1.39).

Table 12- Study cohort prescribing rates by oral anticoagulant and region, 2015/162016/17

Region
Illawarra
Shoalhaven
a.
b.

Illawarra/
Shoalhave
n
Population
N
228,808

Apixaban
Na
(Rate/1,000/
year)
2,000 (8.7)

79,848

582 (7.3)

Prescribing rates by oral anticoagulant
Rivaroxaban
NOACs
Na
Nb
(Rate/1,000/
(Rate/1,000/
year)
year)
2,837 (12.4)
4,764 (20.8)
1,253 (15.7)

1,818 (22.8)

Warfarin
Na
(Rate/1,000/
year)
3,860 (16.9)
1,685(21.1)

The yearly rate is the average of the rates from 2015/16 and 2016/17
Counts of persons prescribed each NOAC do not add to the total counts for all NOAC due to some
people prescribed more than one NOAC during the 2-year study period, and due to small cells being
withheld for some age group by oral anticoagulant by region combinations in the aggregate PBS data.

Further comparisons between prescription data per year for apixaban, rivaroxaban and warfarin
can be found in Appendix 6.
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4.1.2 Stage 2- Hospitalised cohort

4.1.2.1 Number of hospitalisations for adverse drug events

In total, there were 9,432 presentations to ED or admissions to hospital for VTE, haemorrhage or
stroke in ISLHD between 1 July 2015 and 30 June 2017 (Figure 10). Based on eMR notes, 551
individuals were hospitalised on 585 occasions that met the study inclusion criteria. Of these, 90
individuals presented to ED a total of 95 times, and 461 individuals were admitted on 490
occasions. Overall, 6.2% (585/9,432) of hospitalisations for haemorrhage, VTE or stroke across
the ISLHD were for individuals taking the oral anticoagulants apixaban, rivaroxaban and
warfarin.

Figure 10- Hospitalised cohort by ED presentation or admission

Page | 67

Thesis | Kerry Watts

4.1.2.2 Overall hospitalised cohort demographics

Males accounted for 52.6% of hospitalisations, compared to females 47.4%. However, males
had a hospitalisation rate of 51.5 per 1,000 prescribed per year, compared to females 48.6 per
1,000 prescribed per year, respectively (Table 13). The total number of hospitalisations
increased with age, with 83.2% of the hospitalised cohort being 65 years of age or older. The
average age of the hospitalised cohort was 75.2 years. Residents of the Illawarra contributed to
the majority of hospitalisations (74.2%), consistent for both ED presentations (70.5%) and
hospital admissions (74.5%).

Table 13- Hospitalised cohort demographics by ED or admission, 2015/16-2016/17
ED
presentations
N (%)

Admissions
N (%)

Total
hospitalisations a
N (%)

Rate of hospitalisation
per 1,000 prescribed
per yearb

Male

47 (49.5)

260 (53.1)

307 (52.6)

48.6

Female

48 (50.5)

230 (46.9)

278 (47.4)

51.5

21 (22.1)

77 (15.7)

98 (16.8)

44.2

65-69

6 (6.3)

34 (6.9)

40 (6.7)

27.3

70-74

15 (15.8)

52 (10.6)

67 (11.5)

36.0

75-79

19 (20.0)

94 (19.2)

113 (19.3)

52.0

80-84

18 (18.9)

96 (19.6)

114 (19.5)

56.0

85+

16 (16.8)

137 (28.0)

153 (26.2)

77.8

Illawarra

67 (70.5)

367 (74.9)

434 (74.2)

52.2

Shoalhaven

28 (29.5)

123 (25.1)

151 (25.8)

44.4

95 (100.0)

490 (100.0)

585 (100.0)

Sex

Age
<65

Region

Total
a.
b.

Hospitalisation counts are not adjusted for prescribing rates.
The yearly rate is the average of the rates from 2015/16 and 2016/17
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4.1.2.3 Hospitalised cohort demographics and length of stay by oral anticoagulant

Individuals taking NOACs accounted for 48.4% of the hospitalised cohort (Table 14). There
were 72 ADEs that required hospitalisation for individuals taking apixaban, 211 ADEs for
individuals taking rivaroxaban and 302 ADEs for individuals taking warfarin.

The average age for the hospitalised cohort was 78.1 years for individuals taking apixaban, and
76.8 for those taking warfarin, and 72.1 years for those taking rivaroxaban. Residents of the
Illawarra comprised 74.2% of total hospitalisations, a pattern which was evident for both
NOACs and warfarin.

The mean length of stay (LOS) for the admitted cohort was 7.3 days. Individuals taking NOACs
had a mean LOS of 6.3 days, and those on warfarin 7.8 days (Table 14). The mean LOS for
individuals admitted taking apixaban was 5.6 days and for rivaroxaban 6.9 days.
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Table 14- Hospitalised cohort demographics by oral anticoagulant, 2015/16-2016/17
Apixaban
N (%) Rateb

Rivaroxaban
N (%) Rateb

NOACs
N (%) Rateb

Warfarin
N (%) Rateb

Male

41 (56.9) 29.9

107 (50.7) 48.7

148 (52.3) 42.0

159 (52.6) 52.8

Female

31 (43.1) 25.6

104 (49.3) 54.9

135 (47.7) 44.1

143 (47.4) 56.4

˟

51 (24.1) 46.1

˟

˟

65-69

6 (8.3) 16.5

15 (7.1) 25.8

21 (7.4) 22.7

19 (6.3) 32.3

70-74

15 (20.8) 35.0

27 (12.8) 39.3

42 (14.8) 38.3

25 (8.3) 29.8

75-79

11 (15.3) 22.9

46 (21.8) 63.6

57 (20.1) 48.6

56 (18.5) 51.2

80-84

16 (22.2) 35.6

31 (14.7) 55.7

47 (16.6) 47.9

67 (22.2) 58.8

85+

21 (29.2) 50.6

41 (19.4) 94.3

62 (21.9) 74.6

91 (30.1) 75.0

Illawarra

58 (80.6) 29.0

151 (71.6) 53.2

209 (73.9) 43.9

225 (74.5) 58.3

Shoalhaven

14 (20.4) 24.1

60 (28.4) 47.9

74 (26.1) 40.7

77 (25.5) 45.7

72 (12.3)

211 (36.1)

283 (48.4)

302 (51.6)

5.6

6.9

6.3

7.8

Sex

Age
<65

Region

Total ADEs
Mean LOS (days) a

a. admitted patients only
b. The yearly rate is the average of the rates from 2015/16 and 2016/17 per 1,000 prescribed per year
˟ suppressed cells <5 or to maintain confidentiality

The number of hospitalisations for ADEs while taking NOACs increased by 20.4 percentage
points across the two years, with a similar decrease in warfarin-related hospitalisations during
the study period (Figure 11).
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80.0%
70.0%
60.0%
50.0%
40.0%
30.0%
20.0%
10.0%
0.0%

NOACs
warfarin

2015/16

2016/17
Financial year

Figure 11- Hospitalised cohort prescribed NOACs and warfarin by financial year

4.1.2.4 Rates of adverse events by oral anticoagulant

The hospitalisation rate for ADEs among individuals prescribed oral anticoagulants during the
two-year study period was 25.0 per 1,000 prescribed per year (r= (585/11,715/2) x 1,000). The
hospitalisation rate for individuals prescribed NOACs was 21.5 per 1,000 prescribed per year,
lower than the rate for warfarin of 27.2 per 1,000 prescribed per year (P<0.001, 95% CI 0.720.86. Rivaroxaban was associated with a higher rate of hospitalisation 25.8 per 1,000 prescribed
per year compared to apixaban 13.9 per 1,000 prescribed per year (P<0.001, 95% CI 1.70-2.03)
(Table 15).
Table 15- Rates for hospitalised adverse drug events by oral anticoagulant, 2015/162016/17

Hospitalisations (persons) a
Prescriptions (persons)b
Rate d
a.
b.
c.
d.

Apixaban Rivaroxaban
N (%)
N (%)
72 (12.3)
211 (36.1)

NOACs
N (%)
283 (48.4)

Warfarin
N (%)
302 (51.6)

Total
N
585

2,582 (22.3)

4,090 (35.3)

6,582 (56.9)c

5,545 (47.9)

11,715

13.9

25.8

21.5

27.2

25.0

Hospitalisation counts are total counts in the two years 2015/16 and 2016/17
Prescription counts are the average over 2015/16 and 2016/17
Counts of persons prescribed each oral anticoagulant do not add to the total counts for all oral anticoagulants
due to some people prescribed more than one oral anticoagulant during the 2-year study period and due to cell
suppression.
The yearly hospitalisation rate is the average hospitalisation rates over 2015/16 and 2016/17 per 1,000
prescribed per year
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The relative risk (RR) and odds ratio (OR) for hospitalisations differed between oral
anticoagulants. Apixaban was associated with significantly less risk of hospitalisation for ADEs
than warfarin (RR 0.51, 95% CI 0.40-0.66, P<0.0001) (Table 16). However, there was no
significant difference between the risk of rivaroxaban and warfarin-related hospitalisation (RR
0.95, 95% CI 0.80-1.12, P=0.53). There was no difference in risk of hospitalisation for
rivaroxaban compared to warfarin (aOR 0.89, 95% CI 0.74-1.07, P=0.219), after adjusting for
age, sex and region. Comparing the two NOACs, there was significantly more likelihood of
hospitalisation associated with rivaroxaban than apixaban (aOR 2.06, 95% CI 1.57-2.71,
P<0.0001).

Table 16- Relative risk and odds ratio for oral anticoagulant-related hospitalisation

RR (95% Cl)

Apixaban vs
warfarin
0.51 (0.40-0.66)

Rivaroxaban vs
warfarin
0.95 (0.80-1.12)

NOACs vs
warfarin
0.79 (0.67-0.92)

Rivaroxaban vs
apixaban
1.86 (1.43-2.42)

Significance (P)

P<0.0001*

P=0.5347

P=0.0034*

P<0.0001*

Non-adjusted OR (95% Cl)

0.43 (0.33-0.56)

0.80 (0.67-0.96)

0.66 (0.58-0.77)

1.86 (1.42-2.43)

Significance (P)

P<0.0001*

P= 0.017*

P<0.0001*

P<0.0001*

Adjusted OR (95% CI)

0.45 (0.34-0.58)

0.89 (0.74-1.07)

0.71 (0.60-0.85)

2.06 (1.57-2.71)

Significance (P)

P<0.0001*

P=0.219

P<0.0001*

P<0.0001 *

* statistically significant when P=0.05 or less

Variance inflation factors were calculated to assess for multicollinearity between independent
variables in the regression model. There was no evidence of multicollinearity, as all values were
close to 1 (VIF age = 1.001, VIF sex = 1.012 and VIF region = 1.005). The multivariate regression
models were adjusted for these three covariates.
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4.1.2.5 Rates for adverse events by financial year

In the 2015/16 financial year, individuals taking warfarin had a higher hospitalisation rate of
30.4 per 1,000 prescribed per year, compared to NOACs, 19.0 per 1,000 prescribed per year
(P<0.001, 95% CI 1.46-1.75) (Figure 12). In contrast, during the financial year 2016/17,
hospitalisations were comparable between oral anticoagulants, with warfarin hospitalisations
declined to 23.6 per 1,000 prescribed per year, while NOACs increased to 23.5 per 1,000
prescribed per year (P=0.92, 95% CI 0.92-1.10).
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35

Hospitalisation rate per 1000 people
prescribed

apixaban
rivaroxaban

30

warfarin
25
20
15
10
5
0
2015/16

2016/17

Apixaban Rivaroxaban
N (%)
N (%)

NOACs
N (%) a

Warfarin
N (%)

Total
N

180 (62.0)

290

2015/2016
Hospitalisations (persons)
Prescriptions (persons)
Rate per 1,000 per year

26 (9.0)

84 (29.0)

110 (38.0)

2,038(17.3)

3,809 (32.4)

5,794 (49.3)

12.8

22.1

19.0

30.4

25.8

46 (15.9)

127 (43.1)

173 (58.6)

122 (41.4)

295

3,125(24.6)

4371 (34.5)

7,369 (58.1)

15.0

29.1

23.5

5,912 (50.3) 11259

2016/2017
Hospitalisations (persons)
Prescriptions (persons)
Rate per 1,000 per year
a.

5,178 (40.9) 12171
23.6

24.2

Counts of persons prescribed each oral anticoagulant do not add to the total counts for all oral
anticoagulants due to some people prescribed more than one oral anticoagulant during the 2-year study
period and due to cell suppression.

Figure 12- Hospitalisation rate by oral anticoagulant by financial year
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4.1.2.6 Rates for ED presentations versus hospital admissions

ED presentation rates during the two-year study period averaged 4.1 per 1,000 people prescribed
oral anticoagulants per year (n=95). The rates of ED presentations were considerably higher for
individuals taking rivaroxaban 7.1 per 1,000 prescribed per year compared to apixaban 2.3 per
1,000 prescribed per year (P<0.001, 95% CI 2.83-3.37) or warfarin 2.3 per 1,000 prescribed per
year (P<0.001, 95% CI 2.83-3.37). In addition, five individuals taking rivaroxaban re-presented
to ED with an additional anticoagulant-related ADE during the study period (8.6%; 5/58).
Neither individuals taking apixaban or warfarin re-presented to ED during the study period
(Table 17).

The average admission rates for ADEs of oral anticoagulants were 20.9 per 1,000 prescribed per
year (n=490). Admission rates were higher for individuals taking warfarin 25.0 per 1,000
prescribed per year, compared to rivaroxaban 18.7 per 1,000 prescribed per year (P<0.001, 95%
CI 1.22-1.46) and apixaban 11.6 per 1,000 (P<0.001, 95% CI 1.97-2.46). The readmission rates
were 10.0% (6/60) for individuals taking apixaban, 7.2% (11/153) for rivaroxaban and 4.3%
(12/277) for warfarin (Table 17).
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Table 17- Rates of ED and admission by oral anticoagulant, 2015/16-2016/17
2015-2017

Apixaban
N (%)

Rivaroxaban
N (%)

NOACs
N (%)

Warfarin
N (%)

Total
N (%)

12 (13.3)

53 (58.9)

65 (72.2)

25 (27.8)

90 (94.7)

0 (0.0)

5 (100.0)

5 (100.0)

0 (0.0)

5 (5.3)

12 (12.6)

58 (61.1)

70 (73.7)

25 (26.3)

95 (100.0)

2.3

7.1

5.3

2.3

4.1

1 admission

54 (11.7)

142 (30.8)

196 (42.5)

265 (57.4)

461 (94.0)

2 admissions

6 (20.7)

11 (37.9)

17 (58.6)

12 (41.4)

29 (6.0)

Total Admitted

60 (12.2)

153 (31.2)

213 (43.5)

277 (56.5)

490 (100.0)

11.6

18.7

16.2

25.0

20.9

ED
1 presentation
2 presentations
Total ED
Rate of ED presentation per
1,000 people per year a b
Admitted

Rate of admission per 1,000
people per year a b
a.
b.

The yearly rate is the average of the rates from 2015/16 and 2016/17 (apixaban n=2582, rivaroxaban
n=4,090, NOACs n=6582, warfarin n=5,545, total n=11,715)
Counts of persons prescribed each oral anticoagulant do not add to the total counts for all oral
anticoagulants due to some people prescribed more than one oral anticoagulant during the 2-year study
period.

4.1.2.7 Rates of haemorrhage adverse drug events

Haemorrhagic events, the most common ADE requiring hospitalisation for all oral
anticoagulants, were experienced by 18.1 per 1,000 prescribed per year (n=425) between
2015/16 and 2016/17 (Figure 13). There was no significant difference between the rate of
hospitalisation for haemorrhagic events between warfarin (20.0 per 1,000 prescribed per year)
and rivaroxaban (18.4 per 1,000 prescribed per year) (P=0.06, 95% CI 0.99-1.19). Apixaban had
a lower rate of hospitalisation for haemorrhagic events (10.1 per 1,000 prescribed per year)
compared to warfarin (P<0.001, 95% CI 0.46-0.55).

Individuals taking rivaroxaban had a comparable rate of CRNMB (14.9 per 1,000 prescribed per
year) compared to warfarin (14.0 per 1,000 prescribed per year) (P=0.16, 95% CI 0.97-1.16)
(Figure 13). Rates of CRNMB events for individuals taking apixaban however, were
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substantially lower at 3.9 per 1,000 prescribed per year when compared to warfarin (P<0.001,
95% CI 0.25-0.30.

Individuals taking NOACs experienced a lower rate of major haemorrhage event (3.1 per 1,000
prescribed per year) compared to warfarin (6.0 per 1,000 prescribed per year) (P<0.001, 95% CI
0.47-0.56). These major haemorrhagic events for warfarin included intracranial haemorrhages at
a rate of 1.8 per 1,000 prescribed per year and major GI haemorrhage at a rate of 3.1 per 1,000
prescribed per year (Figure 13). The raw data for type of haemorrhage by drug is available in
Appendix 8 (Table 30).
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2.0

4.0

6.0

8.0

10.0

12.0

14.0

16.0

18.0

20.0

22.0

24.0

CRNMB

0.0

Total haemorrhage

0.0

Major
haemorrhage

0.0

Apixaban
Rivaroxaban
Warfarin

Apixaban
N(Rate/1,000
/year) a
40 (7.7)

Rivaroxaban
N(Rate/1,000
/year) a
122 (14.9)

NOACs
N(Rate/1,000
/year) a
162 (12.3)

GI

20 (3.9)

82 (10.0)

102 (7.7)

104 (9.4)

206 (8.8)

Haematuria

11 (2.1)

20 (2.4)

31 (2.4)

24 (2.2)

55 (2.3)

9 (1.7)

20 (2.4)

29 (2.2)

27 (2.4)

56 (2.4)

12 (2.3)

29 (3.5)

41 (3.1)

67 (6.0)

108 (4.6)

Intracranial

˟

˟

6 (0.5)

20 (1.8)

26 (1.1)

GI

˟

˟

21 (1.6)

34 (3.1)

55 (2.3)

5 (1.0)

9 (1.1)

14 (1.1)

13 (1.2)

27 (1.2)

52 (10.1)

151 (18.5)

203 (15.4)

222 (20.0)

425 (18.1)

Adverse drug
event
CRNMB

Other
Major haemorrhage

Other
Total Haemorrhage

Warfarin
Total
N(Rate/1,000 N(Rate/1,000/
/year) a
year) a
155 (14.0)
317 (13.5)

a.

The yearly rate is the average of the rates from 2015/16 and 2016/17 (apixaban n=2,582, rivaroxaban
n=4,090, NOACs n=6582, warfarin n=5,545, total n=11,715)
˟ suppressed cells <5 or to maintain confidentiality

Figure 13- Haemorrhagic event hospitalisation rates by oral anticoagulant, 2015/162016/17
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Further statistical analysis into the location of other CRNMB events was prevented by small
numbers reported for individuals taking NOACs. The table of haemorrhagic data including
supressed cells can be viewed in Appendix 7.

Overall, NOACs resulted in significantly less risk of haemorrhagic events than warfarin (RR
0.77, 95% CI 0.64-0.93, P=0.0073), including after adjusting for sex, age and region (aOR 0.73,
95% CI 0.60-0.89, P=0.002). These significant differences were only apparent for apixaban (RR
0.51, 95% CI 0.38-0.78, P<0.0001) and not for rivaroxaban (RR 0.93, 95% CI 0.76-1.13,
P=0.4599) (Table 18). However, when comparing NOACs, rivaroxaban use had a significantly
higher risk of a haemorrhagic event than apixaban (aOR 2.06, 95% CI 1.50-2.84, P<0.0001)
(Table 18).

Table 18- Relative risk and odds ratio for total haemorrhage adverse drug events by oral
anticoagulant
RR (95% Cl)

Apixaban vs
warfarin
0.51 (0.38-0.68)

Rivaroxaban vs
warfarin
0.93 (0.76-1.13)

NOACs vs
warfarin
0.77 (0.64-0.93)

Rivaroxaban vs
apixaban
1.83 (1.34-2.50)

Significance

P<0.0001*

P=0.4599

P=0.0073*

P<0.0001*

Non-adjusted OR (95% Cl)

0.44 (0.32-0.59)

0.77 (0.63-0.96)

0.64 (0.53-0.78)

1.77 (1.29-2.43)

Significance

P<0.0001*

P=0.017*

P<0.0001*

P<0.0001*

Adjusted OR (95% CI)

0.46 (0.34-0.62)

0.92 (0.74-1.14)

0.73 (0.60-0.89)

2.06 (1.50-2.84)

Significance

P<0.0001*

P=0.436

P=0.002*

P<0.0001*

* statistically significant when P<0.05
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4.1.2.8 Rates of venous thromboembolic adverse drug events

VTE treatment failure were experienced by 8.7% of people with oral anticoagulant ADE-related
hospitalisations (Figure 14). Individuals taking rivaroxaban had a higher rate of VTE-related
hospitalisations (4.0 per 1,000 prescribed per year) compared to apixaban (1.2 per 1,000
prescribed per year) (P<0.001, 95% CI 3.05-3.64) and warfarin (1.2 per 1,000 prescribed per
year) (P<0.001, 95% CI 3.05-3.64). In addition, between 2015-2017, rivaroxaban accounted for
a higher rate of recurrent VTE events requiring hospitalisation (3.4 per 1,000 prescribed per
year), compared to warfarin (0.8 per 1,000 prescribed per year) (P<0.001, 95% CI 3.89-4.64).
The rate for apixaban has not been included due to small numbers and the need for cell
suppression.
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0.5

1.0

1.5

2.0

2.5

3.0

3.5

4.0

4.5

5.0

5.5

6.0

Recurrent VTE

0.0

Adverse Drug
Event
VTE
DVT
PE
Recurrent
VTE

Apixaban
N
(Rate/1,000/
year) a
6 (1.2)

Rivaroxaban
N
(Rate/1,000/
year) a
33 (4.0)

NOACs
N
(Rate/1,000
/year) b
38 (2.9)

Warfarin
N
(Rate/1,000/
year) a
13 (1.2)

Total
N
(Rate/1,000/
year) a
52 (2.2)

5(1.0)

19 (2.3)

˟

˟

˟

˟

14 (1.7)

˟

9 (0.8)

˟

˟

9 (0.8)

˟

˟

28 (3.4)

a.

The yearly rate is the average of the rates from 2015/16 and 2016/17 (apixaban n=2,582, rivaroxaban
n=4,090, NOACs n=6,582, warfarin n=5,545, total n=11,715)
b. Counts of persons prescribed each oral anticoagulant do not add to the total counts for all oral
anticoagulants due to some people prescribed more than one oral anticoagulant during the 2-year
study period.
˟ suppressed cells <5 or to maintain confidentiality

Figure 14- VTE hospitalisation rates by oral anticoagulant, 2015/16-2016/17

The relative risk and odds ratio for VTE ADEs differed between oral anticoagulants. A
comparison of NOACs and warfarin, found that NOACs had a significantly higher relative risk
(RR 2.46, 95% CI 1.31-4.62, P= 0.0150) and odds ratio (OR 2.15, 95% CI 1.15-4.03, P= 0.017)
than warfarin. When adjusted for age, sex and region there was no longer a statistical difference
between the classes of oral anticoagulant (Table 19). The odds ratio of hospitalisation for VTE
while prescribed rivaroxaban was significantly higher than both apixaban (OR 3.44, 95% CI
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1.44-8.21, P=0.005) and warfarin (OR 2.96, 95% CI 1.04-5.63, P=0.001) (Table 19). This
pattern was consistent after adjustment by sex, age and region. The relative risk of recurrent
VTE was significantly higher for rivaroxaban versus warfarin (RR 4.22, 95% CI 1.99-8.93,
P=0.0002). In contrast, there was no difference in risk of hospitalisation for VTEs between
individuals prescribed apixaban and warfarin.
Table 19- Relative risk and odds ratio for VTE adverse drug events by oral anticoagulant

RR (95% Cl)

Apixaban vs
warfarin
0.99 (0.38-2.60)

Rivaroxaban vs
warfarin
3.44 (1.81-6.53)

NOACs vs
warfarin
2.46 (1.31-4.62)

Rivaroxaban vs
apixaban
3.47 (1.46-8.27)

Significance (P)

P= 0.9860

P= 0.0002*

P= 0.0150*

P= 0.0050*

Non-adjusted OR (95% Cl)

0.86 (0.33-2.27)

2.96 (1.56-5.63)

2.15 (1.15-4.03)

3.44 (1.44-8.21)

Significance (P)

P= 0.7619

P=0.001*

P= 0.017*

P= 0.005*

Adjusted OR (95% CI)

0.80 (0.30-2.14)

2.02 (1.04-3.92)

1.66 (0.88-3.15)

2.78 (1.16-6.76)

Significance (P)

P=0.661

P=0.037*

P=0.121

P=0.022*

RR (95% Cl)

Relative Risk (RR) for recurrent VTE ADE by oral anticoagulant
˟
4.22 (1.99-8.93) ˟
˟

Significance (P)

P=0.0002

*statistically significant when P<0.05
˟ supressed cells

4.1.2.9 Rates of ischaemic stroke adverse drug events

The rate of ischaemic stroke treatment failure requiring hospitalisation, while taking an oral
anticoagulant, was 4.3 per 1,000 prescribed per year (Figure 15). Individuals taking warfarin had
a higher rate of ischaemic stroke (5.3 per 1,000 prescribed per year) compared with those taking
apixaban (2.9 per 1,000 prescribed per year; P<0.001, CI 1.121-1.232) or rivaroxaban (3.1 per
1,000 prescribed per year; P<0.001, CI 0.761-0.826). The raw data for type of stroke by drug is
available in Appendix 9 (Table 31).
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Warfarin

Adverse drug event

Ischaemic stroke
a.
b.

Apixaban

Rivaroxaban

NOACs

Warfarin

Total

N
(Rate/1,000/
year) a

N
(Rate/1,000/
year) a

N
(Rate/1,000
/year) b

N
(Rate/1,000
/year) a

N
(Rate/1,000
/year) a

15 (2.9)

25 (3.1)

40 (3.0)

59 (5.3)

99 (4.2)

The yearly rate is the average of the rates from 2015/16 and 2016/17 (apixaban n=2582, rivaroxaban
n=4090, NOACs n=6582, warfarin n=5545, total n=11,715)
Counts of persons prescribed each oral anticoagulant do not add to the total counts for all oral
anticoagulants due to some people prescribed more than one oral anticoagulant during the 2-year study
period.

Figure 15- Ischaemic stroke hospitalisation rates by oral anticoagulant, 2015-16/2016-17

Based on the relative risk and odds ratio, individuals taking NOACs (apixaban and rivaroxaban)
had a significantly lower risk of ischaemic stroke events when compared to warfarin (RR 0.57,
95% CI 0.38-0.85, P=0.0061) (Table 20). These findings were consistent after adjusting odds
ratios for age, sex and region. There was no difference in risk of ischaemic stroke between
apixaban and rivaroxaban.
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Table 20- Relative risk and odds ratio for ischaemic stroke adverse drug events by oral
anticoagulant

RR (95% Cl)

apixaban vs
warfarin
0.55 (0.31-0.96)

rivaroxaban vs
warfarin
0.57 (0.36-0.92)

NOACs vs
warfarin
0.57 (0.38-0.85)

rivaroxaban vs
apixaban
1.05 (0.56-1.99)

Significance

P=0.0371*

P=0.0197*

P=0.0061*

P=0.8769

Non adjusted OR (95% Cl)

0.40 (0.22-0.73)

0.50 (0.32-0.80)

0.46 (0.31-0.69)

1.25 (0.94-2.43)

Significance

P=0.003*

P=0.003*

P<0.0001*

P=0.518

Adjusted OR (95% CI)

0.41 (0.27-0.76)

0.57 (0.36-0.92)

0.51 (0.34-0.78)

1.43 (0.73-2.81)

Significance

P=0.004*

P=0.021*

P=0.002*

P=0.297

* statistically significant when P<0.05

4.1.2.10 Summary of findings

To summarise the findings, the plot of aOR demonstrates that individuals prescribed rivaroxaban
had a significantly higher risk of a VTE event and no difference in haemorrhagic ADE when
compared to warfarin (Figure 16). There was no difference in VTE risk between apixaban and
warfarin, however apixaban had significantly less risk of haemorrhage and ischaemic stroke.

0.80 (0.30-2.14)
2.02 (1.04-3.92)

0.1

VTE apixaban versus warfarin
VTE rivaroxaban versus warfarin

0.46 (0.34-0.62)

Haemorrhage apixaban versus warfarin

0.92 (0.74-1.14)

Haemorrhage rivaroxaban versus warfarin

0.41 (0.27-0.76)

Ischaemic stroke apixaban versus warfarin

0.57 (0.36-0.92)

Ischaemic stroke rivaroxaban versus warfarin

1

10

Adjusted odds ratio (95% CI)- log scale
Figure 16- Adjusted odds ratio plot of adverse drug events
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4.1.3 Stage 2 Hospitalised cohort contributing factors

Results relating to renal function, indication and comorbidities as contributing factors for ADEs
were only available for the admitted patient cohort. The ED cohort was excluded because of
limited and inconsistent documentation of medication histories.

4.1.3.1 Renal function

Moderate to severe renal impairment were common among the hospitalised cohort for
individuals taking warfarin (54.9%) and NOACs (55.2%) (Table 21). A total of nine individuals
admitted to hospital for ADEs while taking oral anticoagulants did not have their renal function
assessed at admission.

Table 21- Admitted cohort renal function by oral anticoagulant, 2015/16-2016/17
Creatinine Clearance

Apixaban Rivaroxaban
N (%)
N (%)

NOACs
N (%)

Warfarin
N (%)

Total
N (%)

>80mL/min (normal)

8(13.1)

52 (33.8)

60 (27.9)

63 (22.9)

123 (25.1)

50-79mL/min (mild)

33 (54.1)

60 (39.0)

93 (43.3)

96 (34.9)

189 (38.6)

30-49mL/min (mod)

17 (27.9)

30 (19.5)

47 (21.9)

55 (20.0)

102 (20.8)

<30mL/min (severe)

˟

˟

9 (4.2)

58 (21.1)

67 (13.7)

Not reported

˟

˟

˟

˟

9 (1.8)

154 (100.0) 215 (100.0)

275 (100.0)

490 (100.0)

Total a

61 (100.0)

˟ suppressed cells <5 or to maintain confidentiality
a. Cells may not appear to add to totals due to suppressed cell values

Further descriptive analysis of rivaroxaban admissions found that when measured on admission
to hospital, 32 individuals admitted for ADEs with an AF indication had moderate or severe
renal impairment. It should be acknowledged that this may not have been the renal function at
point of prescribing, but concomitant acute illness could have precipitated a decline in renal
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function. Nevertheless, moderate or severe renal impairment reduces the elimination of NOACs
and the risk of accumulation of the anticoagulant could contribute to haemorrhagic ADEs. The
recommended dose for rivaroxaban in AF for this cohort is 15mg once daily. In 37.5% (n=12) of
cases the prescribed doses of rivaroxaban exceeded the maximum dose, including 20mg once
daily or 15mg twice daily, the latter being the dose for treatment of VTE, not for AF.

4.1.3.2 Indication

AF was the most common indication among individuals admitted to hospital for ADEs (71.0%)
(Table 22), compared to VTE (20.2%) (Table 22). Other unlicensed indications, including
mechanical mitral valve, were found in 10.2% (n= 22/215) of all NOAC-related admissions
during the study period (Table 22).

Table 22- Indications for admitted cohort by oral anticoagulant, 2015/16-2016/17
Indication
AF

Apixaban
N (%)

Rivaroxaban
N (%)

NOACs
N (%)

Warfarin
N (%)

Total
N (%)

51 (83.6)

91 (59.1)

142 (66.0)

206 (74.9)

348 (71.0)

˟

49 (31.8)

˟

48 (17.5)

99 (20.2)

8 (13.1)

14 (9.1)

22 (10.2)

21 (7.6)

43 (8.8)

61

154

215

275

490

VTE
Other
Total a

˟ suppressed cells <5 or to maintain confidentiality
a. Cells may not appear to add to totals due to suppressed cell values

4.1.3.3 Comorbidities

Hypertension, cardiac disease, hyperlipidaemia and diabetes were common co-morbidities
among the individuals admitted to hospital with anticoagulant-related ADEs. Individuals with a
history of bleeding/anaemia were admitted for ADEs while taking NOACs (apixaban 18.2% or
rivaroxaban 14.7%), compared with warfarin (11.4%) (Table 23). In total, 34.5% of individuals
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hospitalised taking apixaban had experienced a stroke as a co-morbid condition, compared to
26.6% taking warfarin or 13.3% taking rivaroxaban. Only 3.7% of admissions for individuals
taking NOACs and 5.1% of individuals taking warfarin had a diagnosis of thrombophilia as a comorbidity. Population-adjusted rates were not calculated for comorbidities because individuals
had more than one documented comorbidity. A pairwise comparison of comorbidities is
available in Appendix 10 (Table 32).

Table 23- Comorbidities for admitted cohort by oral anticoagulant, 2015/16-2016/17
Apixaban Rivaroxaban
N (%)
N (%)

NOACs
N (%)

Warfarin
N (%)

Total
N (%)

Medical history
Cardiac (CF, IHD)

29 (47.5)

47 (30.5)

76 (35.3)

111 (40.3)

187 (38.2)

HTN

44 (72.1)

83 (53.9)

129 (60.0)

148 (53.8)

235 (47.9)

DM

22 (36.1)

37 (24.0)

59 (27.4)

83 (30.2)

142 (28.9)

Hyperlipid/hypercholesterol

19 (31.1)

48 (31.2)

67 (31.2)

87 (31.6)

154 (31.4)

Stroke (CVA, TIA)

19 (31.1)

19 (12.3)

38 (17.7)

70 (25.4)

108 (22.0)

˟

˟

8 (3.7)

25 (9.1)

33 (6.7)

10 (16.4)

21 (13.6)

31 (14.4)

30 (10.9)

61 (12.4)

˟

˟

8 (3.7)

14 (5.1)

22 (4.5)

61 (100.0)

154 (100.0)

PVD
Bleeds/Anaemia
Thrombophilia
Total a

215 (100.0) 275 (100.0)

490(100.0)

˟ suppressed cells <5 or to maintain confidentiality
a.

Cells may not appear to add to totals due to suppressed cell values

4.1.3.4 International Normalised Ratio

The INR was found to be in therapeutic range in less than half of individuals taking warfarin
who had been admitted to hospital for ADEs (42.9%) (Table 24). Even though 10 (3.6%) of the
individuals admitted for ADEs while taking warfarin, did not have their INR taken, 30.5% were
in the supratherapeutic range and 22.9% were in the subtherapeutic range. The average INR for
the cohort taking warfarin on admission to hospital for ADE s was 3.17. The highest recorded
INR level taken was 13.2 and the lowest was 0.9.
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Table 24- INR results of admitted cohort taking warfarin, 2015/16-2016/17

INR
Supratherapeutic >3

Warfarin
N (%)
84 (30.5)

Therapeutic 2-3

118 (42.9)

Subtherapeutic <2
Not available
Total

63 (22.9)
10 (3.6)
275 (100)
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4.2 STUDY 2- SMALL SCALE PILOT STUDY

4.2.1 Demographic characteristics of small-scale pilot study participants

Between May 2018 and February 2019, seventeen patients were invited to participate in Study 2.
These patients had presented to the Vascular Care Centre with recurrent VTE while taking
NOACs for treatment or prophylaxis of VTE. The target sample size was 15 participants, to pilot
the knowledge and adherence tools in such a specific patient cohort. Eight patients declined the
invitation to be included in the study. The reasons for declining included medical issues or no
reason given. A total of nine participants were included in the study (Table 25). Of these nine
participants who had experienced recurrent VTE, seven had been taking apixaban and two were
taking rivaroxaban. The average age of participants was 68 years. It should be acknowledged
that the findings from this small study sample size is not generalisable. This study does however,
provide a descriptive investigation of the knowledge and adherence of this previously unstudied
patient cohort, drawing attention to the need and importance of a larger sample study and
thereby attract funding to undertake this research.

Table 25- Participant demographic and clinical characteristics
Demographic characteristics
Male n (%)
Female n (%)
Mean age in years (age range)

Participants (n=9)
5 (55%)
4 (45%)
68 (55-77)

Number taking apixaban

7

Number taking rivaroxaban

2
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4.2.2 Oral anticoagulation knowledge tool

Overall, the average score for anticoagulant knowledge among the Study 2 participants was
58.5%. All of the participants knew the name, indication and dosing frequency of their oral
anticoagulant. All the participants recognised that it was not appropriate to stop taking their
medication once they felt better; or to take more of the anticoagulant than prescribed by their
doctor. All of the participants also knew that they needed to inform other health professionals
about their use of anticoagulants. The majority of participants (88.9%) recognised that it was not
acceptable to double the dose, if a dose was missed and that it was important to take NOACs at
the same time each day. Fewer of the participants (66.7%) understood that they needed to
consult with their doctor before taking vitamin and/or herbal supplements with their
anticoagulants.

Less than half of the study participants understood how the medicine works in the body (33.3%),
and why it was important to take NOACs exactly as directed (44.4%). A prompt from Question
4 regarding what time of day the NOAC was taken indicated both participants taking
rivaroxaban did not take this medication with food. Only two participants (22.2%) knew the
most important side effects of their anticoagulants, while only one participant knew that skipping
a dose of a NOAC could worsen their condition or could list ways to reduce their risk of
experiencing side effects. None of the participants had any changes to their regular medications
prior to the recurrent VTE.
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Table 26- Item-level analysis of 20 item anticoagulation knowledge questions
Question
What is the name of your anticoagulant medicine?
Why has your doctor prescribed this medicine?
How many times a day do you need to take this medicine?
Is it important that all health care practitioners you see know
that you are taking this medicine?
Is it appropriate to stop taking this medicine once you feel
better?
Is it safe to take anti-inflammatory medicines like ibuprofen
while you are taking this medicine?
Is there any benefit in taking more of this medicine that your
doctor has told you to take?
Is it necessary to inform a surgeon, dentist or other health
professional that you are taking this medicine before
undergoing a procedure?
For how long do you need to take this medicine (3, 6 months,
life-long)?
Is it acceptable to double the next dose of this medicine if
you miss a dose?
Is it acceptable to take this medicine at different times as
long as you take it on the required days?
Will drinking too much alcohol increase the risk of side
effects with this medicine?
Is it safe to take vitamin supplements and herbal medicines
with this medicine without consulting your doctor?
Why is it important to take this medicine exactly as your
doctor has told you?
How does the medicine work in the body?
What is the most important side effect of this medicine?
Is it possible that skipping one dose of this medicine could
worsen your condition?
Three signs of side effects that you should watch for
Three things you can do to reduce your risk to side effect
What is the best step to take if you accidently take too much
of this medicine?

N (%) Question
correct Number
9 (100.0)
1
9 (100.0)
2
9 (100.0)
4
9 (100.0)
16
9 (100.0)

10

9 (100.0)

11

9 (100.0)

13

9 (100.0)

15

8 (88.9)

5

8 (88.9)

8

7 (77.8)

7

7 (77.8)

14

6 (66.7)

12

4 (44.4)

6

3 (33.3)
2 (22.2)
1 (11.1)

3
17
9

1 (11.1)
1 (11.1)
0 (0.0)

18
19
20

^Validated knowledge tool approved for use on 30th May 2018 (Obamiro et al. 2016).

4.2.3 Oral anticoagulant adherence questionnaire

In response to the four-item Morisky Medication Adherence Questionnaire, all participants were

adherent in taking their NOAC medication, and did not stop taking their medication either when
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they were feeling better or when they were feeling worse (Table 27). A lack of adherence was
found among four participants who had forgotten to take their NOAC, and three had been
careless at times about taking their oral anticoagulant.

Table 27- Item-level analysis of anticoagulation adherence questions
Question
Do you ever forget to take your oral anticoagulant?
Are you careless at times about taking your oral anticoagulant?

N (%) correct
5 (55.5)
6 (66.7)

When you feel better do you sometimes stop taking your oral anticoagulant?

9 (100.0)

Sometimes when you feel worse do you stop taking your oral anticoagulant?

9 (100.0)

*Score low-high; yes=0; no=1
^Adherence questionnaire approved for use 31st May 2018 (Morisky et al.)

Table 28 shows that all study participants that experienced recurrent VTE had medium to high
adherence scores for taking their NOACs.

Table 28- Anticoagulation adherence questionnaire scores
Adherence score
1= low adherence

N (%)
0 (0.0)

2-3= medium adherence

5 (55.0)

4= high adherence

4 (45.0)

^Adherence questionnaire approved for use 31st May 2018 (Morisky et al.)
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5. DISCUSSION

The main aim of this thesis was to compare the rate and risk of hospitalisation for oral
anticoagulant-related ADEs among individuals taking NOACs (apixaban and rivaroxaban) and
warfarin over a 2-year period in the Illawarra Shoalhaven region. The key findings from this
thesis were that individuals taking NOACs had a significantly lower risk of any ADE compared
to warfarin and a lower risk of total haemorrhagic ADE requiring hospitalisation. Notably, the
risk of total haemorrhagic ADEs was comparable for individuals taking rivaroxaban or warfarin,
but was significantly less for individuals taking apixaban. A sub-analysis of the total
haemorrhagic ADEs identified that the hospitalisation rates for CRNMB, including minor GI
haemorrhage, were lower for apixaban and comparable for rivaroxaban and warfarin. The risk of
major haemorrhagic events was lower for apixaban, when compared to warfarin, but the risk was
comparable for apixaban and rivaroxaban. The most important finding from this thesis is that
individuals taking rivaroxaban had a significantly higher risk of hospitalisation for a VTE ADE
compared to warfarin and apixaban. In contrast, individuals taking warfarin had a higher risk of
being hospitalised for an ischaemic stroke ADE compared to the NOACs.

It is estimated that total ADEs account for between 4.2 and 30.0% of hospital admissions in the
USA and Canada and between 5.7 and 18.8% of admissions in Australia (Sultana et al. 2013).
The current study found that oral anticoagulants contributed to 6.2% (n=585/9432) of ISLHD
hospitalisations for ADEs (haemorrhage, VTE or ischaemic stroke).

In total, individuals taking the two NOACs studied (apixaban and rivaroxaban) experienced a
significantly lower risk of hospitalisation for ADEs when compared to warfarin (RR 0.79, 95%
CI 0.67-0.92). These findings concur with results from a South Australian study which found a
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significantly higher risk of hospital admissions for individuals taking warfarin compared to
NOACs (RR 3.42, 95% CI 2.41-4.87) (Roberts et al. 2016). Although fewer individuals were
prescribed rivaroxaban in this study (13.3 per 1,000 population per year), than warfarin (18.0 per
1,000 population per year), the hospitalisation rates were comparable (aOR 0.89, 95% CI 0.741.07). Individuals taking rivaroxaban had a significantly higher risk of hospitalisation compared
with apixaban (aOR 2.06, 95% CI 1.57-2.71). Furthermore, individuals taking apixaban had a
lower risk of hospitalisation compared to warfarin (aOR 0.45, 95% CI 0.34-0.58). Potentially, a
reason for lower risk of hospitalisation for apixaban compared to rivaroxaban and warfarin could
be that after only gaining PBS listing in 2015, apixaban prescribing was still gaining momentum.

Risk factors for hospitalisation while taking oral anticoagulants in the Illawarra Shoalhaven

Across the two-year study period NOAC prescribing increased from 20.8 per 1,000 population
per year (2015/16) to 22.7 per 1,000 population per year (2016/17) and there was a reduction in
warfarin prescribing (from 19.2 per 1,000 population per year to 16.8 per 1,000 population per
year). Concurrently, hospitalisations for individuals taking NOACs increased by 20.4 percentage
points between 2015/16 (38.6%) and 2016/17 (59.0%), while hospitalisations for individuals
taking warfarin decreased by 20.4 percentage points (from 61.4% to 41.0%). Further studies
need to assess if this trend continues.

While more Shoalhaven residents were prescribed apixaban, rivaroxaban or warfarin when
compared to Illawarra residents, the unadjusted hospitalisation rate was lower for Shoalhaven
residents in comparison to the Illawarra residents. The higher prescribing rate and lower
hospitalisation rate for Shoalhaven residents may be due to various differences between the
Shoalhaven region and the Illawarra region, some of which may include: more prescribing of
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dabigatran; more individuals taking oral anticoagulants visiting private hospitals or hospitals
outside the studied local health district; better patient counselling and medication management to
avoid ADEs; or more ADEs potentially managed outside of hospital. However, this would
require further research which incorporates ADEs managed in other facilities, for example
private hospitals and general practice, and qualitative research into medication management.

The current study found prescribing and hospitalisation rates for individuals taking oral
anticoagulants increased substantially with age. For instance, 83.2% of individuals hospitalised
for ADEs, while taking oral anticoagulants, were aged 65 years and over. Although the
percentage of hospitalisations for individuals less than 80 years of age was higher while taking
the two NOACs (61.5%) than warfarin (47.7%), due to higher prescribing rates of NOACs in
this cohort, the rate of hospitalisation remained lower for NOACs than warfarin (21.5 per 1,000
prescribed per year and 27.2 per 1,000 prescribed per year, respectively). In addition, the
percentage of hospitalisations remained lower for individuals aged over 80 years taking NOACs
compared to warfarin (38.5% and 52.3%, respectively). Although individuals aged over 80 years
were previously underrepresented in clinical trials when comparing the ADEs of NOACs to
warfarin (Deitelzweig et al. 2019), a recent observational study concluded that NOACs were
safe in this older cohort (Monelli et al. 2019). These findings may in part support the findings of
the current study.

Existing literature has found that males have a higher risk of AF (Kannel & Benjamin 2008) and
higher annual incidence rate of VTE compared to females (males 130 per 100,000; females 110
per 100,000) (Heit 2015). This may in part explain why findings from this current study found
that substantially more males were prescribed oral anticoagulation (42.0 per 1,000 population
per year) compared to females (34.1 per 1,000 population per year).
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Hospitalisation rate of haemorrhagic ADEs between oral anticoagulants

Haemorrhage, including minor and major haemorrhage, is the most common ADE reported with
oral anticoagulant use (Khan & Datta 2015) and the findings from this research are consistent
with the literature. Haemorrhage accounted for the majority of ADEs for apixaban (72.2%),
rivaroxaban (71.6%) and warfarin (73.5%) which were relatively consistent for the different oral
anticoagulants. These appear to be in contrast to those of an Australian observational study,
which found that NOACs were associated with a decrease in hospitalisations for bleeding events
compared to warfarin (incidence rate ratio 2.89; 95% confidence interval 2.02-4.12; p < 0.001)
(Roberts et al. 2019). In terms of minor haemorrhage or CRNMB events, the current study found
individuals taking NOACs (apixaban and rivaroxaban) also had comparable risk of
hospitalisation for total CRNMB events when compared to warfarin (RR 1.12, 95% CI 0.961.29). These findings are also in contrast to the international literature which suggests that
NOACs have lower CRNMB events in comparison to warfarin (Adam et al. 2013; Es et al. 2014;
Rollins et al. 2014). However, in the current study individuals taking apixaban had lower rates of
CRNMB hospitalisations (7.7 per 1,000 prescribed per year), compared to individuals taking
rivaroxaban (14.9 per 1,000 prescribed per year) or warfarin (14.0 per 1,000 prescribed per
year), which support the evidence that apixaban is likely to cause fewer bleeding events
compared to rivaroxaban (Bahit et al. 2017; Dawwas et al. 2019) and warfarin (Bahit et al.
2017; Dawwas et al. 2019).

Individuals with a haemorrhagic history or previous anaemia were hospitalised for CRNMB
events while taking NOACs (14.4%) more than individuals taking warfarin with the same
history (11.4%). These results are consistent with the HAS-BLED calculator which aims to
assess individual haemorrhagic risk, including haemorrhagic history and predisposition, for
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example anaemia, as important risk factors (Lip et al. 2011). However, this prediction tool was
implemented in 2010 before the introduction of NOACs and includes labile INR and alcohol
consumption as part of the tool, which are not affected by NOACs and may need to be reviewed.
This finding is further supported by studies, which found higher rates of GI haemorrhage with
NOAC use (Abraham et al. 2015; Granger et al. 2011), and contraindications for NOAC use in
patients with clinically significant active haemorrhage or history of GI haemorrhage
(McCaughan 2017). These findings suggest that NOACs may not be the best choice for
individuals with a haemorrhagic history or anaemia and require further larger-scale studies to
investigate the safety of NOAC use in individuals with a haemorrhagic history.

This study found individuals taking apixaban had the lowest rate of hospitalisations for major
haemorrhagic ADEs (2.3 per 1,000 prescribed per year), compared to individuals taking warfarin
(6.0 per 1,000 prescribed per year) or rivaroxaban (3.5 per 1,000 persons per year). This result
mirrors a prospective UK cohort study of 150,454 participants , which found that individuals
taking apixaban had a decreased risk of major bleeding events (aHR 0.66, 95% CI 0.54 to 0.79
and aHR 0.66, 95% CI 0.54 to 0.79, respectively), compared with warfarin (Vinogradova et al.
2018). However, the current study findings that individuals taking rivaroxaban are less likely to
be hospitalised for major haemorrhagic ADEs, compared to warfarin are inconsistent with a
USA study which found no significant differences in major haemorrhagic events for the two
anticoagulants (OR 0.98, 95% CI 0.83-1.17) (Lip et al. 2016). While it is not clear what has
contributed to this inconsistency, the findings do support a Phase III clinical trial (Van Es et al.
2014) , which found that intracranial haemorrhage, a major haemorrhagic event, is less likely to
occur with NOACs compared to warfarin (0.5 per 1,000 prescribed per year and 1.8 per 1,000
prescribed per year, respectively).
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Hospitalisation rate of VTE Treatment failure between oral anticoagulants

Treatment failure is a recognised risk of all medications, including NOACs (McIlroy et al.
2018). The current research found a higher rate of VTE treatment failure for individuals
prescribed oral anticoagulants, 2.2 per 1,000 prescribed per year, compared to the reported
annual incidence of VTE of 1.5 per 1,000 people per year (P<0.001, 95% CI 1.34-1.60) (Stevens
et al. 2019). The rate of VTE in this study would be expected to be higher than the national
average because the study focused on VTE ADEs for all oral anticoagulant indications. It is
worth noting however, that these direct comparisons are difficult to interpret, given the
heterogeneous nature of study participants for the many different studies which have
investigated oral anticoagulant related outcomes, the different methodologies used and the many
different outcome measures and definitions for these outcomes (e.g. bleeding events)
(EINSTEIN DVT investigators 2010; EINSTEIN PE investigators 2012; Streiff et al. 2016).

The research of Lutsey et al (2019) was the first published investigation of the rate of VTE while
treated for a non-VTE indication, for example AF, and supports the model of treatment failure
utilised in this study. Lutsey et al, investigated 117,912 AF patients and found a lower hazard
ratio of VTE among those taking apixaban compared to warfarin (HR 0.51, 95% CI 0.39-0.68),
but a similar risk of VTE incidence among those taking rivaroxaban compared to warfarin (HR
1.01, 95% CI 0.87-1.19) (Lutsey et al. 2019). Individuals taking rivaroxaban in the current study,
were twice as likely to be hospitalised for a VTE ADE compared to warfarin, regardless of
whether they were prescribed for VTE treatment/prophylaxis or AF. However, unlike
rivaroxaban, there were no significant differences in risk of hospitalisation for VTE ADEs
among those taking apixaban compared to warfarin. Although these findings are supported by
previous evidence (Streiff et al. 2016) the number of individuals included in this current study
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taking apixaban were small and need to be taken into consideration when interpreting the results.
These findings may suggest that apixaban and warfarin are less likely than rivaroxaban to result
in VTE ADEs, which would make them more favourable options for the treatment and
prevention of VTE. However, this would require further research on a much larger scale, given
the small number of individuals taking apixaban in this study (n=72) which in the majority of
cases was prescribed for AF, rather than the treatment or prevention of VTE.

Studies have concluded no difference in rates of VTE recurrence between NOACs and warfarin
(Castellucci et al. 2014; Streiff et al. 2016). However, this research found that individuals taking
rivaroxaban had a significantly higher rate of hospitalisation for recurrent VTE events (3.4 per
1,000 prescribed per year), compared to individuals taking warfarin (0.8 per 1,000 prescribed per
year) (RR 4.22, 95% CI 1.99-8.93). These significant findings potentially suggest that warfarin
could be the safer option in the management of VTE compared to rivaroxaban, and comparable
to apixaban.

NOACs are popular alternatives to warfarin for the primary prevention of strokes (Paschke et al.
2020) and are recommended in Australia as first line for stroke prevention in at risk patients with
non-valvular AF (Brieger et al. 2018). The findings from this research, suggest that individuals
taking rivaroxaban and apixaban were found to be significantly less likely to be hospitalised for
ischaemic stroke when compared to warfarin (aOR 0.57, 95% CI 0.36-0.92 and aOR 0.41, 95%
CI 0.27-0.76, respectively). These results support the evidence that lower risks of stroke have
been reported with individuals taking apixaban compared to warfarin (Granger et al. 2011; Yao
et al. 2016). However, they are in contrast to the evidence which suggests similar stroke risks for
rivaroxaban and warfarin (Shpak et al. 2018; Yao et al. 2016) and they also conflict with a recent
retrospective German observational study of 837,430 patients, which found that individuals
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taking NOACs had a higher risk of stroke (HR 1.32; CI 1.29–1.35) compared to vitamin K
antagonists (Paschke et al. 2020). These inconsistent results may potentially be due to the current
study investigating ischaemic stroke ADEs for individuals taking oral anticoagulants for all
indications rather than being limited to AF. These discrepancies warrant further investigation
using unit record data to account for duration of oral anticoagulant treatment, switching oral
anticoagulation, adherence, comorbid conditions and drug interactions.

Potential contributing factors to hospitalisation for ADEs

It is well documented that renal impairment increases the risk of anticoagulant-related ADEs,
including ischaemic stroke and haemorrhage (Heine et al. 2018) and that individuals with severe
renal impairment and comorbidities should be prescribed warfarin (Amin et al. 2017; Heine et al.
2018; Hillis & Crowther 2014). It is not surprising therefore, that 41.1% (n=113) of individuals
hospitalised while taking warfarin, in the current study, had moderate to severe renal
impairment. It is surprising however, that even though NOACs require dose adjustments in renal
impairment and are contraindicated in severe renal impairment (Vandiver et al. 2014), 26.1%
(n=56) of hospitalised individuals taking NOACs, in the current study, had moderate to severe
renal impairment on admission. Furthermore, the dose of rivaroxaban was not appropriately
reduced to account for the severity of renal impairment in 37.5% (n=12) as per dosage
recommendations at the time of the study. These dosage recommendations however, were
revised in June 2020, and now suggest that rivaroxaban is contraindicated in severe renal failure
(i.e. CrCl <15mL/min rather than CrCl <30mL/min) (Weber et al. 2019). Even though the
investigation into suboptimal dose management of NOACs in renal impairment was limited by
small numbers and requires further investigation, the findings suggest that there is a need for
monitoring of renal function on commencement and throughout treatment with NOACs.
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Prescribing medication for an unlicensed indication is considered a risk factor for ADEs, since
the safety and efficacy of the drug for these indications remains unknown (Bellis et al. 2014).
There is a paucity of existing evidence relating to the use of NOACs for individuals with
prosthetic heart valves, which is currently not recommended (Vandiver et al. 2014).
Nevertheless, 10.2% (n=22) of admitted individuals taking NOACs in the present study had
documented unlicensed indications for their use, which included treatment for mitral valve
disorders, ischaemic heart disease, peripheral vascular disease and stroke prevention without a
history of AF. These findings may be based on very small numbers, however they suggest that
hospitalisations for apixaban, when prescribed for unlicensed indications, resulted in more
hospitalisations for ADEs 13.1% (n= 8), than when prescribed for the licensed VTE indications
3.3% (n=2). These findings therefore suggest that off-label use of NOACs may be a contributing
factor to ADE hospitalisations, which is why NOAC prescribing should be limited by approved
indications and monitored for potential drug interactions until further research can support the
safety and efficacy of NOACs in these patient cohorts.

This study found that the most common comorbidities among individuals taking apixaban,
rivaroxaban or warfarin, hospitalised for ADEs, included diabetes mellitus, hyperlipidaemia
(hypercholesterolaemia) and peripheral vascular disease. Despite NOACs not being
recommended for use in individuals living with thrombophilia, which increases the risk of
clotting events (Signorelli et al. 2016), thrombophilia was found to be a comorbid condition in
eight individuals taking NOACs (3.6%), seven of whom were admitted for VTEs. While it needs
to be acknowledged that these numbers are small, it is concerning that NOACs are being
prescribed when contraindicated.
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Exploring medication adherence and knowledge as a contributing factor to VTE treatment
failure for outpatients

To date, poor adherence to warfarin has been well documented (Kearon et al. 2016; Thachil
2012) and it is recognised that therapeutic INR control can be used as a surrogate measure of
adherence (Shikdar & Bhattacharya 2019). The evidence suggests that supratherapeutic INR
levels (INR >3), which was the case for 30.5% (n=84/275) of individuals admitted to hospital in
Study 1, increases the risk of haemorrhagic ADEs. This proportion of individuals with
supratherapeutic INRs is almost twice that reported in a study undertaken by Nelson et al (2015),
which found that 16% of 9433 participants had supratherapeutic INRs. Importantly however,
Nelson et al’s study (2015) investigated INR control in patients treated for non-valvular AF over
a six-month period and included both hospitalised and non-hospitalised patients. The current
study also found that 22.9% (n=63/275) of individuals admitted to hospital (Study 1) had
subtherapeutic INRs <2, which increases the risk of experiencing ADEs and treatment failure.
These subtherapeutic proportions were similar to those cited in the Nelson et al study (2015).
Unlike warfarin, there is no simple biochemistry measure or monitoring system which can be
used to measure adherence to NOACs. This is of concern given that a UK cohort study
(n=36,652) found that non-adherence for individuals taking NOACs for AF was lower when
compared to individuals taking warfarin (rivaroxaban OR 0.61, 95% CI 0.58-0.65; apixaban OR
0.57, 95% CI 0.54-0.61) (Banerjee et al. 2020). In the absence of being able to monitor NOAC
adherence in study 1, the Master’s candidate was only able to collect self-reported selfadherence data in study 2, a very small pilot study. To the best of her knowledge this is the first
Australian study to investigate vascular outpatients that have presented with treatment failure
based on a recurrence of their VTE. The findings, which need to be considered carefully given
the small number of participants, suggest that knowledge of NOACs appears to have not
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improved from previous Australian research (Obamiro et al. 2016) and medium or high
medication adherence may still result in recurrent VTE.

Patient knowledge and understanding of oral anticoagulation has been found to have the greatest
impact on adherence (Clarkesmith et al. 2017; Smet et al. 2018). The average score for the
Anticoagulant Knowledge Tool (AKT) used in this study was 58.5%, which was similar to the
results for the 50 patients (62.0%) who were included in the Australian study which validated the
tool (Obamiro et al. 2016). Participant knowledge was sound relating to basic information
including drug name, indication and dosing frequency of their oral anticoagulant. Their lack of
knowledge related to understanding how the NOACs work (33.3%), potential side effects
associated with taking NOACs (22.2%) and the impact of missing a NOAC dose (11.1%). The
knowledge deficits found in this study are unknown, and may be attributed to a lack of health
literacy or inadequate information provided to patients by health care professionals as suggested
in the literature (Smet et al. 2018).
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6. CONCLUSION

Population-based research is required to understand the impact of a novel therapy in a patient
population that is far more generalisable than the selected patient populations used in clinical
trials. This thesis found, compared to warfarin, those taking rivaroxaban had a higher risk of
hospitalisation for a VTE ADE and a similar risk of haemorrhage. Individuals taking apixaban
were found to have a similar risk of VTE events compared to warfarin, but a lower risk of
haemorrhage and ischaemic stroke. The use of rivaroxaban and apixaban resulted in similar risks
of ischaemic stroke events requiring hospitalisation. Furthermore, comorbidities such as
thrombophilia, renal impairment and medication knowledge were found to be factors which need
to be considered when prescribing and selecting oral anticoagulant therapy. Selecting the
optimal oral anticoagulation needs to be made on an individual basis, understanding the
indication being treated and potential patient risk factors.

Overall, this research is an example of the important implications of population-level evidence.
In the post-marketing approval of NOACs, several observational studies have been published,
however, the limitations and methodological challenges associated with the different types of
real-world studies must be considered carefully when interpreting the findings (Camm & Fox
2018). This thesis complements existing studies, providing an insight into treatment outcomes
based on population-level evidence, rather than evidence from systematic reviews and metaanalyses and clinical trial data which often exclude older people and those living with comorbidities.
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7. IMPLICATIONS FOR CLINICAL PRACTICE

The higher hospitalisation rates of VTE ADEs for individuals taking rivaroxaban compared to
warfarin found from this study are a concern for patient safety. These findings warrant further
research and may ultimately require a review of the therapeutic guidelines and the
recommendation for NOACs as first-line therapy for VTE management. In the interim,
prescribers need to be informed about the risks of related VTE ADEs and encouraged to actively
assess adherence or request a pharmacist review by way of a home medication review, for
example.

These findings highlight the importance of consumer medication information and adherence
monitoring from prescribing clinicians and pharmacists. The key recommendations for clinicians
and pharmacists in helping to reduce the risk of ADEs requiring hospitalisation for individuals
taking oral anticoagulants are to ensure adequate counselling, emphasising why it is important to
take NOACs as prescribed, and the significance of missing doses. Pharmacists, in particular,
should plan to re-emphasise the importance of adherence at each prescription refill. A further
recommendation for clinicians and pharmacists is to promote an individualised approach to
NOAC selection rather than the marketed ‘one drug fits all’ attitude, focusing on bleeding risk,
previous VTE, renal function and adherence issues.
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8. STENGTHS AND LIMITATIONS

The main strengths of this research were the population-level data and the in-depth
individualised patient review of hospitalisations across a Local Health District which included
admissions across nine hospitals for study 1 in particular. This allowed the researcher to provide
a more detailed analysis of hospital admissions and ED presentations for individuals taking oral
anticoagulation. In addition, the patient centred interview and individual survey completion
(Study 2) provided pilot study data regarding knowledge and adherence to NOACs.

In addition to these strengths however, the research had several limitations:

1. The study did not include dabigatran because it is not subsidised by the PBS for use in
VTE which would have skewed the findings by all indications.
2. This study did review potential drug interactions, including NSAIDs, macrolides, aspirin,
clopidogrel, fish oil, but could not provide any useful analysis at this level, with limited
individual data to assess the impact of these potential interactions on ADEs.
3. The study was undertaken in one Local Health District, within a regional area of NSW.
The region is representative of Australia in terms of socio-demographics, but we cannot
be sure that it is representative of prescribing patterns. In addition, we only have data on
hospitalisations at public hospitals and are missing admissions to private hospitals or
admissions to hospitals outside the region, e.g., Queanbeyan, South Eastern Sydney.
4. The PBS item codes included in this study did not incorporate the subset code level. PBS
item codes are further divided into subset codes to allow for differentiation between
prescribed indications or criteria. For example, the rivaroxaban PBS item code included
in this study was 2268J. However, rivaroxaban prescription data could be analysed by
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retrieving the subset PBS data by indication: VTE 4099, 4132, 4268 and AF 4269. The
use of PBS subset codes would allow for population-adjusted rates for treatment failure
of VTE ADEs while taking oral anticoagulation for VTE only or stroke ADEs when
taking oral anticoagulation for AF only. The subset codes were not applied to this study
because warfarin prescribing does not have subset codes and could therefore not be
analysed at this level.
5. The use of aggregate data for this study did not include exposure time. The PBS data was
retrieved based on individuals receiving one or more prescription of an oral anticoagulant
within each financial year, and across the two-year study period. There were no start and
end dates included in the data retrieval, therefore it was assumed that the drug was
prescribed to each individual for the entire year. By using aggregate annual data, it was
not possible to more finely adjust for time at risk within a financial year, therefore we
assumed a patient was at risk of an ADE for the entire financial year during which their
anticoagulant was dispensed. This may have overestimated the time at risk for some
patients and therefore may have under-estimated the rate of hospitalisation compared to
persons hospitalised per year at risk. While this assumption may under-estimate the
hospitalisation rate for all oral anticoagulants, if patients more commonly switch from
NOACs to warfarin, and spend less time on NOACs, then it would have more impact on
under-estimation of NOAC hospitalisation rates. In addition, the data did not account for
non-adherence which may differ by oral anticoagulant, and may limit the generalisability
of the findings. A larger study would benefit from unit record PBS data, which include
start and end dates, prescribed amounts and changes in oral anticoagulation, as well as
longitudinal hospital data, which could be adjusted for additional comorbid risk factors.
A prospective study on a sample of patients would be required to incorporate measures of
medication adherence.
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6. Adherence was not measured as part of Study 1. The PBS data did not identify whether
individuals regularly filled their prescriptions or continued treatment for each year of the
study.
7. Apixaban became subsidised for use by the PBS in 2015, and unlike warfarin and
rivaroxaban, was only just starting to be prescribed at the beginning of the study period.
This may have contributed to smaller prescription numbers and hospitalisations for
apixaban related VTE ADEs, which may impact on the generalisability of the results.
8. The study outcomes were limited to ADEs resulting in hospitalisation and cannot provide
an insight into the number of ADEs that did not require hospitalisation, including
individuals that died at home, or provide comparative patient factors, such as medication
history, indication for use and renal function for non-hospitalised patients in the
community setting. The results of this study therefore, may underrepresent the true extent
of anticoagulant related ADEs occurring outside of hospitals and currently being
managed by GPs or vascular consultants in clinics.
9. IHIP data extraction enabled the review of all hospitalisations in ISLHD according to
documented admission ICD-10 AM (9th edition) and ED SNOMED codes. There is
potential for human error in coding these files, which may have resulted in a lack of
retrieval of ADEs, in particular SNOMED codes relevant for ED presentations. Coding
quality is much higher in the admitted patient data where qualified coders translate
documentation to ICD-10-AM (9th edition) codes and up to 100 diagnoses can be
recorded compared to up to 4 in the ED SNOWMED coded record.
10. The Master’s candidate (pharmacy researcher) reviewed eMR documentation which
differed in quality between site and the health professional that entered the data, allowing
for potential human error for omitted documentation, which may have resulted in a lack
of or unnecessary inclusion into the data analysed. Furthermore, screening for medication
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history and reason for admission from eMR may have resulted in under-reporting issues
by the treating physician or reporting bias by the researcher. In addition, this method was
very time-consuming. However, the potential confounder of researcher bias was
mitigated by a randomised review of all included results, including medication history,
indication for use, reason for admission and renal function, for 10% of the hospitalised
cohort by a second health professional researcher, which agreed with the results.
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9. PROPOSED FUTURE RESEARCH

There are several future studies either as an expansion to this research or based on the findings
of this research that require further investigation:

1. A larger-scale study, including a larger population for apixaban, is required to allow for
further analysis of ADEs of NOACs compared to warfarin in the Australian community.
2. To investigate VTE events while taking oral anticoagulation managed outside of hospital
settings.
3. Efficacy of aspirin use in comparison to oral anticoagulation for post-operative VTE
prophylaxis.
4. A larger scale NOAC knowledge and adherence study is required to investigate the
impact of improved patient knowledge of NOACs on ADEs.
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APPENDIX 3
Interview Guide- Vascular Outpatient Clinic Cohort

Before turning on recorder
Hello, my name is Kerry Watts I am a pharmacist from the Wollongong Hospital
Pharmacy Department and am currently undertaking a Masters of Philosophy degree at
the University of Wollongong. I understand you had indicated you would be happy to be
interviewed about your medications used to treat and help prevent blood clots.

Are you happy to proceed?

Turn on recorder
The interview will take place in two parts. The first part is to collect some information
about yourself and the completion of the Morisky Medication Adherence Tool, which
requires yes/no answers relating to how you take your medications. The second part of
the interview, will be more about the safe use of your medicines.

Part 1:
The following questions I am going to ask you are about yourself, these results will be
de-identified

Sex: M F
Year of Birth:

1: Please tell me why you came into the vascular outpatient clinic?

Prompts
Bleed, VTE
Is this the first time this has happened?
Have you seen your GP more than usual because of this problem?

Page | 124

Thesis | Kerry Watts

1

General Questions
What is the name of your anticoagulant medicine?

Answers

Prompts
Oral anticoagulants: Eliquis, Xarelto, Aspirin, Clopidogrel

2
3
4

Why has your doctor prescribed this medicine?
How does the medicine work in the body?
How many times a day do you need to take this medicine?
Prompts
everyday…? how about in the past week?
Prompts
time of the day -morning, midday, evening, before bed
With food? Without food? With water or any other juices?

5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20

For how long do you need to take this medicine (3, 6
months, life-long)?
Why is it important to take this medicine exactly as your
doctor has told you?
Is it acceptable to take this medicine at different times as
long as you take it on the required days?
Is it acceptable to double the next dose of this medicine if
you miss a dose?
Is it possible that skipping one dose of this medicine could
worsen your condition?
Is it appropriate to stop taking this medicine once you feel
better?
Is it safe to take anti-inflammatory medicines like ibuprofen
while you are taking this medicine?
Is it safe to take vitamin supplements and herbal medicines
with this medicine without consulting your doctor?
Is there any benefit in taking more of this medicine that your
doctor has told you to take?
Will drinking too much alcohol increase the risk of side
effects with this medicine?
Is it necessary to inform a surgeon, dentist or other health
professional that you are taking this medicine before
undergoing a procedure?
Is it important that all the health care practitioners you see
know you are that you are taking this medicine?
What is the most important side effect of this medicine?
Three signs of side effects that you should watch out for
while taking this medicine are:
Three things you can do to reduce your risk to side effect
are:
What is the best step to take if you accidentally take too
much of this medicine?
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4: I am now going to ask you some questions that require one-word answers,
relating to the way you take your ……. (answer to question 2):

Do you ever forget to take your ……. (answer to question 2)?
Are you careless at times about taking your ……. (answer to
question 2)?
When you feel better do you sometimes stop taking your …….

No=1, Yes=0
No=1, Yes=0
No=1, Yes=0

(answer to question 2)

Sometimes if you feel worse when your ……. (answer to
No=1, Yes=0
question 2), do you stop taking it?
Score: high-low; yes=0; no=1. Range 0-4. 1=low adherence; 2-3=medium
adherence; 4=high adherence
Self-reported medication-taking scale, Morisky, Green & Levine Medication Adherence Tool

Now we will commence on the second part of the interview questions.
Part 2:
5a: Please tell me about any of your other medical conditions that you regularly need to
see a doctor for?
Prompt
GP, Specialists- Heart specialist, kidney specialist, liver specialist

5b: Please tell me the names of any other medications you may take and what you take
them for?

6: Please tell me if you have made any recent changes to your lifestyle behaviours, such
as changes to your diet, exercise, alcohol intake and/or physical activity?

7: Please tell me about any changes have you had to your medications recently?
Prompt
especially in the last month?

Thank you for your time.
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APPENDIX 4

PARTICIPANT INFORMATION SHEET- Vascular
Outpatient Clinic Cohort
TITLE: Investigating the safe use of medications to treat and help prevent blood clots
PURPOSE OF THE RESEARCH
This is an invitation to participate in a study being conducted by Kerry Watts, a
Wollongong Hospital pharmacist, who is undertaking her Masters of Philosophy
Research degree under the supervision of A/Prof Judy Mullan, Margaret Jordan, Dr
Luise Lago and Dr Laurencia Villalba. The purpose of this study is to investigate the
safe use of medications used to treat and prevent blood clots.
This project is important because taking these medications as prescribed by the doctor
is important to making sure they work correctly. The information from this study will be
used to identify ways to help ensure that these medications are taken safely and
appropriately.
INVESTIGATORS
Kerry Watts

A/Prof Judy Mullan

Margaret Jordan

Wollongong Hospital Pharmacy
Department

Wollongong Hospital Pharmacy
Department

Kerry.watts1@health.nsw.gov.au

CHRISP
Graduate Medicine,
UOW
jmullan@uow.edu.au

4222 5449
Dr Laurencia Villalba

4221 5980
Dr Luise Lago

4255 1531

Wollongong Hospital Vascular
Department

CHRISP

laurenciavillalba@live.com

lago@uow.edu.au

Margaret.jordan@health.nsw.gov.au

METHOD AND DEMANDS ON PARTICIPANTS
If you choose to be included in this study, you will be asked to take part in an individual 30minute interview conducted by Kerry Watts over the phone at a time which is convenient to
you. The interview questions have been designed to learn more about what you know and
how you take your medications to prevent and/or treat blood clots.
The interview will be recorded for later transcription and analysis. Your medical records
from the vascular outpatient clinic will be reviewed as part of the study to learn more about
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the management of your blood clot(s). All data will not include your name to maintain your
confidentiality. Please note that you will not be paid for your interview session.
POSSIBLE RISKS, INCONVENIENCES AND DISCOMFORTS
Apart from the time to attend the interview we can foresee no risks for you. However, if
participation in this study causes you any distress please seek further advice from your
doctor. Your involvement in the study is voluntary and you may withdraw your participation
from the study at any time. However, once the information has been collected you will not
be able to withdraw your contribution because no names will be included in the transcripts
and the analysis. Not participating in the study will not affect your relationship with the
University of Wollongong or Illawarra Shoalhaven Local Health District.
BENEFITS OF THE RESEARCH
The results of the study will be used to help pharmacists and other healthcare workers
understand how to best educate patients on their medications for the treatment and
prevention of blood clots and reduce medication related problems. Findings from the study
will be published in a thesis, in academic journals and as conference presentations. A copy
of the study conclusions will be available to any interested person by contacting the
investigators. Please note that individuals will not be identified in any reports or publications
arising from this research.
ETHICS REVIEW AND COMPLAINTS
This study has been reviewed by the Human Research Ethics Committee of the University
of Wollongong.
If you have any concerns or complaints regarding the way this research has been
conducted, you can contact the UOW Ethics Officer on (02) 4221 3386 or email: rsoethics@uow.edu.au
Thank you for your interest in this study. If you would like further information about this
study, please contact Kerry Watts on (02) 4222 5449 or email:
Kerry.watts1@health.nsw.gov.au
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APPENDIX 5

CONSENT FORM for individual interviews
TITLE: Investigating the safe use of medications to treat and help prevent blood clots
INVESTIGATORS
Kerry Watts
Wollongong Hospital
Pharmacy Department

Kerry.watts1@health.ns
w.gov.au
4222 5449
Dr Laurencia Villalba

Associate Professor
Judy Mullan
CHRISP
School of Medicine,
UOW
jmullan@uow.edu.au

Margaret Jordan

Dr Luise Lago

Wollongong Hospital
Pharmacy Department

CHRISP

Margaret.jordan@healt
h.nsw.gov.au

lago@uow.edu.au

4221 5980

4255 1531

4221 5835

Wollongong Hospital
Vascular Department

laurenciavillalba@live.c
om

I have been given information about the project “Investigating the safe use of
medications to treat and help prevent blood clots” and I have discussed the research
with one of the investigators.
I have been advised of any possible risks or burdens associated with this research and have
had the opportunity to ask an investigator any questions about my participation.
I understand that my participation is voluntary, I will not receive any payment and that my
interview responses will be recorded. I know that I am free to refuse to participate and that I
can withdraw from the research at any time without affecting my relationship with the
University of Wollongong or the Illawarra Shoalhaven Local Health District.
If I have any questions about the research, I can contact Kerry Watts at the Wollongong
Hospital Pharmacy Department on 4222 5449 or email Kerry.watts1@health.nsw.gov.au or if I
have any concerns or complaints regarding the way the research is being conducted, I can
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contact the Ethics Officer, Human Research Ethics Committee, Office of Research, University
of Wollongong on 4221 3386 or email: rso-ethics@uow.edu.au
By signing below, I am giving my consent to participate in this research project by taking part
in an interview which will be recorded and give permission for the researchers to review my
medical records. I also give my consent for the results of the study to be written as part of a
thesis, as well as in journal publications and as conference presentations.

Signed:

Name (please print):

Date:
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APPENDIX 8
Table 29- Comparison between PBS data apixaban, rivaroxaban and warfarin- raw data
2015- 2017

PBS oral anticoagulant prescriptions (persons)
Apixaban

Rivaroxaban

Warfarin

N

(%)

N

(%)

N

(%)

Male

1872

(53.3)

2960

(52.4)

3556

(54.2)

Female

1643

(46.7)

2688

(47.6)

3003

(47.6)

Total

3515

(100.0)

5648

(100.0)

6559

(100.0)

<65

638

(18.2)

1616

(28.6)

813

(12.4)

65-69

462

(13.1)

780

(13.8)

646

(9.8)

70-74

579

(16.5)

949

(16.8)

966

(14.7)

75-79

627

(17.8)

933

(16.5)

1227

(18.7)

80-84

612

(17.4)

756

(13.4)

1348

(20.6)

85+

597

(17.0)

614

(10.9)

1559

(23.8)

2706

(77.0)

3857

(68.3)

4587

(69.9)

809

(23.0)

1791

(31.7)

1972

(30.1)

3515

(100.0)

5648

100.0

6559

(100.0)

SEX

AGE

REGION
Illawarra
Shoalhaven
TOTAL

% total population taking each oral anticoagulant, apixaban (n=3515), rivaroxaban (n=5648) and warfarin (n=6559)
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APPENDIX 9

Table 30- Haemorrhage by oral anticoagulant- raw data
2015- 2017

Apixaban

Rivaroxaban

Total Rate2

Warfarin

N

(%)

N

(%)

N

(%)

N

(%)

Cerebrovascular

˟

˟

˟

˟

20

(9.0)

26

(6.1)

0.9

Epistaxis

˟

˟

˟

˟

29

(13.1)

42

(9.9)

1.4

20

(38.5)

82

(53.6)

104

(47.1)

205

(48.3)

7.0

Haematoma

˟

˟

˟

˟

12

(5.4)

15

(3.5)

0.5

Haematuria

11

(21.2)

20

(13.2)

24

(10.8)

55

(3.0)

1.9

Haemoptysis

˟

˟

˟

˟

13

(5.4)

21

(4.9)

0.7

Mouth

˟

˟

13

(8.6)

˟

˟

20

(4.7)

0.7

Other (PV)

7

(13.5)

17

(11.3)

16

(7.2)

40

(9.4)

1.4

425 (100.0)

14.5

TYPE OF BLEED

GI
(haematemesis,
melaena, rectal)

Bleeds Total
Rate1

52 (100.0)

151 (100.0)

222 (100.0)

7.4

13.3

16.9

MAJOR BLEED
Intracranial

˟

˟

˟

˟

20

(9.0)

26

(6.1)

GI

˟

˟

˟

˟

34

(15.3)

55

(13.0)

Other

5

(9.6)

9

(6.0)

13

(5.9)

27

(6.4)

Major bleed total

12

(23.1)

29

(19.4)

67

(30.2)

108

(24.5)

3.7

Rate1

1.7

(69.8)

316

(74.5)

10.8

2.6

5.1

CRNMB
CRNMB total

40

Rate1

5.7

(76.9)

121
10.7

(80.6)

155
11.8

˟ suppressed cells <5 or to maintain confidentiality
1. Rates per 1,000 persons per year from persons taking individual oral anticoagulant (apixaban n=3515,
rivaroxaban n=5648, warfarin n=6559)/2
2. Rates per 1,000 persons per year per population; total persons taking oral anticoagulants (n=14577 patients
prescribed oral anticoagulants in combined 2015/16 and 2016/17 financial years)/2
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APPENDIX 10
Table 31- Stroke ADE by oral anticoagulant- raw data
2015-2017

Apixaban

Rivaroxaban

Warfarin

Total

N

(%)

N

(%)

N

(%)

N

(%)

3

(16.7)

3

(10.7)

20

(25.3)

26

(20.8)

15

(83.3)

25

(89.3)

59

(79.7)

99

(79.2)

Stroke
haemorrhagic
ischaemic
Total

18 (100.0)

28 (100.0)

79 (100.0)

125 (100.0)

Rate1

2.6

2.5

6.0

4.3

1.

-

-

-

-

Rates per 1,000 persons per year from persons taking individual oral anticoagulant (apixaban n=3515,
rivaroxaban n=5648, warfarin n=6559)/2
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APPENDIX 11
Table 32- Pairwise comparison of admitted cohort comorbidities by oral anticoagulant,
2015/16-2016/17
Apixaban vs
rivaroxaban
Comorbidity

Apixaban vs
warfarin
χ2 (p)

Rivaroxaban vs
warfarin
χ2 (p)
χ2 (p)

Cardiac (CF, IHD)

7.200 (P= 0.0073)*

2.226 (P= 0.1357)

3.585 (P= 0.0583)

HTN

9.163 (P= 0.0025)* 11.710 (P=0.0006)*

0.116 (P= 0.7333)

DM

4.125 (P= 0.0423)*

1.586 (P= 0.2080)

1.537 (P= 0.2151)

0.016 (P= 0.9002)

0.044 (P= 0.8341)

0.011 (P= 0.9161)

12.542 (P=0.0004)*

1.540 (P= 0.2146)

10.211 (P= 0.0014)*

PVD

0.446 (P= 0.5043)

0.995 (P= 0.3185)

5.209 (P= 0.0225)*

Bleeds/Anaemia

0.403 (P= 0.5257)

2.085 (P= 0.1487)

0.975 (P= 0.3234)

˟

˟

˟

Hyperlipid/cholesterol
Stroke (CVA, TIA)

Thrombophilia
˟ suppressed cells <5 or to maintain confidentiality
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APPENDIX 12
Treatment failure
When prescribed for AF, rivaroxaban resulted in the least number of stroke ADEs, defined as
treatment failure, 19.4% compared to warfarin 23.9% and apixaban 23.7%. In contrast however,
individuals prescribed rivaroxaban for VTE treatment or prophylaxis experienced the highest
percentage of VTE events, defined as treatment failure, 43.1% (n=28/65) compared with VTE
failures of 17.0% with warfarin (n=9/53). Based on vascular consultant advice, individuals
taking rivaroxaban experienced a clinically significant (>0.5) higher rate of treatment failure 6.4
per 1,000/year compared to 5.6 per 1,000/year taking warfarin.

Percentage of hospitalisations for treatment failure by oral anticoagulant

apixaban

AF failure

rivaroxaban
warfarin

VTE failure

0%

10%

Indication AF/stroke
Outcome stroke
Failure %
Indication VTE/post-op prophylaxis
Outcome VTE
Failure %
Total failure rate per 1,000/year ab

20%

apixaban
59
14
23.7
˟
˟
˟
˟

30%

rivaroxaban
124
24
19.4
65
28
43.1
6.4

40%

50%

NOACs
183
38
20.8
˟
˟
˟
˟

warfarin
222
53
23.9
53
9
17.0
5.6

a.

The yearly rate is the average of the rates from 15/16 and 16/17 (apixaban n=2582, rivaroxaban n=4090,
NOACs n=6582, warfarin n=5545, total n=11,715)
b. Counts of persons prescribed each oral anticoagulant do not add to the total counts for all oral
anticoagulants due to some people prescribed more than one oral anticoagulant during the 2-year study
period.
˟ suppressed cells <5 or to maintain confidentiality

Figure 17- Treatment failure by oral anticoagulant, 2015/16-2016/17
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